삼성서울병원

Ko En
의료진 검색
찾으실 의료진명을 입력하여 검색해주세요.

혈액종양내과 박세훈 교수

진료분야
비뇨의학암
진료일정 04 月
날짜
월
01
화
02
수
03
목
04
금
05
토
06
일
07
월
08
화
09
수
10
목
11
금
12
토
13
일
14
월
15
화
16
수
17
목
18
금
19
토
20
일
21
월
22
화
23
수
24
목
25
금
26
토
27
일
28
월
29
화
30
오전
오후
진료일정 05 月
날짜
수
01
목
02
금
03
토
04
일
05
월
06
화
07
수
08
목
09
금
10
토
11
일
12
월
13
화
14
수
15
목
16
금
17
토
18
일
19
월
20
화
21
수
22
목
23
금
24
토
25
일
26
월
27
화
28
수
29
목
30
금
31
오전
오후
본원외래 본원클리닉 본원육아상담 암병원외래 암병원클리닉 암병원육아상담

학력

학력
2010.02 가천의과학대학교 대학원 의학과 (박사)
2004.02 성균관대학교 의과대학원 의학과 (석사)
1994.02 건국대학교 의과대학 의학과 졸업 (의학사)

경력

경력
2016.04 ~현재 삼성서울병원 혈액종양내과 교수
2010.04 ~ 2016.03 삼성서울병원 혈액종양내과 부교수
2008.03 ~ 2010.03 삼성서울병원 혈액종양내과 조교수
2003.03 ~ 2008.02 가천의과학대학교 길병원 혈액종양내과 조교수
2002.03 ~ 2003.02 삼성서울병원 혈액종양내과 전임의
2002.02 내과 전문의 자격 취득
1998.03 ~ 2002.02 삼성서울병원 내과 전공의 (레지던트) 수료
1997.05 ~ 1998.02 삼성서울병원 인턴과정 수료

학회활동

학회활동
2002.03 ~ 현재 American Society of Clinical Oncology, European Society for Medical Oncology 정회원
2002.03 ~ 현재 대한내과학회, 대한암학회, 대한항암화학요법연구회, 한국임상암학회 정회원
논문
  • LANCET ONCOL 2024 10.1016/S1470-2045(23)00540-5 Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study Grande, E; Arranz, JA; De Santis, M; Bamias, A; Kikuchi, E; del Muro, XG; Park, SH; De Giorgi, U; Alekseev, B; Mencinger, M; Izumi, K; Schutz, FA; Puente, J; Li, JR; O'Donnell, PH; Kalebasty, AR; Ye, DW; Mariathasan, S; Bene-Tchaleu, F; Bernhard, S; Lee, C; Davis, I; Galsky, M
    View PubMed
  • ANN ONCOL 2024 10.1016/j.annonc.2023.10.003 Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial Siefker-Radtke, AO; Matsubara, N; Park, SH; Huddart, RA; Burgess, EF; Özgüroglu, M; Valderrama, BP; Laguerre, B; Basso, U; Triantos, S; Akapame, S; Kean, Y; Deprince, K; Mukhopadhyay, S; Loriot, Y
    View PubMed
  • LANCET ONCOL 2024 10.1016/S1470-2045(23)00539-9 Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study Bamias, A; Davis, I; Galsky, M; Arranz, JA; Kikuchi, E; Grande, E; Muro, XGD; Park, SH; De Giorgi, U; Alekseev, B; Mencinger, M; Izumi, K; Schutz, FA; Puente, J; Li, JR; Panni, S; Gumus, M; Oezgueroglu, M; Mariathasan, S; Poloz, Y; Bene-Tchaleu, F; Lee, C; Bernhard, S; De Santis, M
    View PubMed
  • EUR UROL 2024 10.1016/j.eururo.2023.08.001 Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Analysis from JAVELIN Bladder 100 by Duration of First-line Chemotherapy and Interval Before Maintenance Sridhar, SS; Powles, T; Durán, MAC; Park, SH; Massari, F; Thiery-Vuillemin, A; Valderrama, BP; Ullén, A; Tsuchiya, N; Aragon-Ching, JB; Gupta, S; Petrylak, DP; Bellmunt, J; Wang, J; Laliberte, RJ; di Pietro, A; Costa, N; Grivas, P; Sternberg, CN; Loriot, Y
    View PubMed
  • BIOMEDICINES 2023 10.3390/biomedicines11123264 Prevalence of RAF1 Aberrations in Metastatic Cancer Patients: Real-World Data Lim, SH; Jung, J; Hong, JY; Kim, ST; Park, SH; Park, JO; Kim, KM; Lee, J
    View PubMed
  • EUR UROL OPEN SCI 2023 10.1016/j.euros.2023.10.002 Overall Survival by Response to First-line Induction Treatment with Atezolizumab plus Platinum-based Chemotherapy or Placebo plus Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma Grande, E; Bamias, A; Galsky, MD; Kikuchi, E; Davis, ID; Arranz, JA; Kalebasty, AR; del Muro, XG; Park, SH; De Giorgi, U; Alekseev, B; Mencinger, M; Izumi, K; Puente, J; Li, JR; Bernhard, S; Nicholas, A; Telliez, J; De Santis, M
    View PubMed
  • SCI ADV 2023 10.1126/sciadv.adk1098 Patient-derived exosomes facilitate therapeutic targeting of oncogenic MET in advanced gastric cancer Hyung, S; Ko, J; Heo, YJ; Blum, SM; Kim, ST; Park, SH; Park, JO; Kang, WK; Lim, HY; Klempner, SJ; Lee, J
    View PubMed
  • NEW ENGL J MED 2023 10.1056/NEJMoa2308849 Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma Loriot, Y; Matsubara, N; Park, SH; Huddart, RA; Burgess, EF; Houede, N; Banek, S; Guadalupi, V; Ku, JH; Valderrama, BP; Tran, B; Triantos, S; Kean, Y; Akapame, S; Deprince, K; Mukhopadhyay, S; Stone, NL; Siefker-Radtke, AO
    View PubMed
  • J CLIN ONCOL 2023 10.1200/JCO.23.00233 Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial Antonarakis, ES; Park, SH; Goh, JC; Shin, SJ; Lee, JL; Mehra, N; McDermott, R; Sala-Gonzalez, N; Fong, PC; Greil, R; Retz, M; Sade, JP; Yanez, P; Huang, YH; Begbie, SD; Gafanov, RA; De Santis, M; Rosenbaum, E; Kolinsky, MP; Rey, F; Chiu, KY; Roubaud, G; Kramer, G; Sumitomo, M; Massari, F; Suzuki, H; Qiu, P; Zhang, JC; Kim, J; Poehlein, CH; Yu, EY
    View PubMed
  • ONCOLOGIST 2023 10.1093/oncolo/oyad231 Patient-Reported Outcomes in KEYNOTE-564: Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma Choueiri, TK; Tomczak, P; Park, SH; Venugopal, B; Symeonides, S; Hajek, J; Ferguson, T; Chang, YH; Lee, JL; Haas, N; Sawrycki, P; Sarwar, N; Gross-Goupil, M; Thiery-Vuillemin, A; Mahave, M; Kimura, G; Perini, RF; Saretsky, TL; Bhattacharya, R; Xu, L; Powles, T
    View PubMed
  • J CLIN ONCOL 2023 10.1200/JCO.22.01792 Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After & GE;2 Years of Follow-Up Powles, T; Park, SH; Caserta, C; Valderrama, BP; Gurney, H; Ullen, A; Loriot, Y; Sridhar, SS; Sternberg, CN; Bellmunt, J; Aragon-Ching, JB; Wang, J; Huang, B; Laliberte, RJ; di Pietro, A; Grivas, P
    View PubMed
  • INT J CANCER 2023 10.1002/ijc.34608 Efficacy and safety of lenvatinib plus pembrolizumab vs sunitinib in the East Asian subset of patients with advanced renal cell carcinoma from the CLEAR trial Rha, SY; Choueiri, TK; Matveev, VB; Alyasova, A; Hong, SH; Gordoa, TA; Gurney, H; Bjarnason, GA; Buchler, T; Pedrazzoli, P; Takagi, T; Park, SH; Lee, JL; Perini, RF; He, CS; McKenzie, JA; Eto, M
    View PubMed
  • EUR UROL 2023 10.1016/j.eururo.2023.03.030 Avelumab First-line Maintenance Therapy for Advanced Urothelial Carcinoma: Comprehensive Clinical Subgroup Analyses from the JAVELIN Bladder 100 Phase 3 Trial Grivas, P; Park, SH; Voog, E; Caserta, C; Gurney, H; Bellmunt, J; Kalofonos, H; Ullen, A; Loriot, Y; Sridhar, SS; Yamamoto, Y; Petrylak, DP; Sternberg, CN; Gupta, S; Huang, B; Costa, N; Laliberte, RJ; di Pietro, A; Valderrama, BP; Powles, T
    View PubMed
  • UROL ONCOL-SEMIN ORI 2023 10.1016/j.urolonc.2023.02.002 Avelumab first-line maintenance plus best supportive care (BSC) vs. BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Asian subgroup analysis Lee, JL; Desai, C; Park, SH; Tsuchiya, N; Su, PJ; Chan, TTW; Gurney, H; Gao, S; Wang, J; Sandner, R; di Pietro, A; Eto, M
    View PubMed
  • CANCER RES TREAT 2023 10.4143/crt.2022.883 Real-World Study Evaluating Safety and Effectiveness of Axitinib in Korean Patients with Renal Cell Carcinoma after Failure of One Prior Systemic Therapy Shin, SJ; Lee, JL; Kwon, TG; Shim, BY; Chung, HS; Kim, SH; Park, SH
    View PubMed
  • CANCER RES TREAT 2023 10.4143/crt.2022.343 Neoadjuvant Nivolumab Plus Gemcitabine/Cisplatin Chemotherapy in Muscle-Invasive Urothelial Carcinoma of the Bladder Kim, H; Jeong, BC; Hong, J; Kwon, GY; Kim, CK; Park, W; Pyo, H; Song, W; Sung, HH; Hong, JY; Park, SH
    View PubMed
  • ONCOLOGY-NY 2023 Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/Gastroesophageal Adenocarcinoma Catenacci, DVT; Kang, YK; Uronis, HE; Lee, KW; Ng, MCH; Enzinger, PC; Park, SH; Gold, PJ; Lacy, J; Hochster, HS; Cheul, S; Kim, YH; Marrone, KA; Kelly, RJ; Juergens, RA; Kim, JG; Alcindor, T; Sym, SJ; Song, EK; Chee, CE; Chao, Y; Kim, S; Oh, DY; Yen, J; Odegaard, JI; Lagow, E; Li, D; Sun, JC; Kaminker, P; Moore, PA; Rosales, MK; Park, H
    View PubMed
  • EUR UROL 2023 10.1016/j.eururo.2022.04.016 Patient-reported Outcomes from JAVELIN Bladder 100: Avelumab First-line Maintenance Plus Best Supportive Care Versus Best Supportive Care Alone for Advanced Urothelial Carcinoma Grivas, P; Kopyltsov, E; Su, PJ; Parnis, FX; Park, SH; Yamamoto, Y; Fong, PC; Tournigand, C; Duran, MAC; Bamias, A; Caserta, C; Chang, JE; Cislo, P; di Pietro, A; Wang, J; Powles, T
    View PubMed
  • LANCET ONCOL 2023 Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study Choueiri, TK; Eto, M; Motzer, R; De Giorgi, U; Buchler, T; Basappa, NS; Mendez-Vidal, MJ; Tjulandin, S; Park, SH; Melichar, B; Hutson, T; Alemany, C; McGregor, B; Powles, T; Grunwald, V; Alekseev, B; Rha, SY; Kopyltsov, E; Kapoor, A; Gordoa, TA; Goh, JC; Staehler, M; Merchan, JR; Xie, R; Perini, RF; Mody, K; McKenzie, J; Porta, C
    View PubMed
  • FUTURE ONCOL 2023 10.2217/fon-2022-1294 Treatment of muscle-invasive urothelial cancer with nivolumab (CheckMate 274 study): a plain language summary Bajorin, DF; Witjes, JA; Gschwend, JE; Schenker, M; Valderrama, BP; Tomita, Y; Bamias, A; Lebret, T; Shariat, SF; Park, SH; Ye, DW; Agerbaek, M; Enting, D; McDermott, R; Gajate, P; Peer, A; Milowsky, MI; Nosov, A; Antonio, JN; Tupikowski, K; Toms, L; Fischer, BS; Qureshi, A; Collette, S; Unsal-Kacmaz, K; Broughton, E; Zardavas, D; Koon, HB; Galsky, MD
    View PubMed
  • J UROLOGY 2023 Re: Pembrolizumab Versus Placebo as Post-nephrectomy Adjuvant Therapy for Clear Cell Renal Cell Carcinoma (KEYNOTE-564): 30-month Follow-up Analysis of a Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Trial Editorial Comment Powles, T; Tomczak, P; Park, SH; Venugopal, B; Ferguson, T; Symeonides, SN; Hajek, J; Gurney, H; Chang, YH; Lee, JL; Sarwar, N; Thiery-Vuillemin, A; Gross-Goupil, M; Mahave, M; Haas, NB; Sawrycki, P; Burgents, JE; Xu, L; Imai, K; Quinn, DI; Choueiri, TK
    View PubMed
  • EUR UROL OPEN SCI 2023 10.1016/j.euros.2022.12.019 Management of Fibroblast Growth Factor Inhibitor Treatment- emergent Adverse Events of Interest in Patients with Locally Advanced or Metastatic Urothelial Carcinoma Siefker-Radtke, AO; Necchi, A; Park, SH; Garcia-Donas, J; Huddart, RA; Burgess, EF; Fleming, MT; Kalebasty, AR; Mellado, B; Varlamov, S; Joshi, M; Duran, I; Tagawa, ST; Zakharia, Y; Qi, KQ; Akapame, S; Triantos, S; O'Hagan, A; Loriot, Y
    View PubMed
  • INT J MOL SCI 2023 10.3390/ijms24043994 Fat Loss in Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors Lee, JH; Hwang, S; Jee, B; Kim, JH; Lee, JH; Chung, JH; Song, W; Sung, HH; Jeon, HG; Jeong, BC; Seo, SI; Jeon, SS; Lee, HM; Park, SH; Kwon, GY; Kang, MY
    View PubMed
  • J CLIN ONCOL 2023 10.1200/JCO.22.00205 Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU) Rosenberg, JE; Park, SH; Kozlov, V; Dao, TV; Castellano, D; Li, JR; Mukherjee, SD; Howells, K; Dry, H; Lanasa, MC; Stewart, R; Bajorin, DF
    View PubMed
  • PATHOL RES PRACT 2023 10.1016/j.prp.2022.154233 Five-gene signature for the prediction of response to immune checkpoint inhibitors in patients with gastric and urothelial carcinomas Kang, SY; Heo, YJ; Kwon, GY; Lee, J; Park, SH; Kim, KM
    View PubMed
  • CANCER RES TREAT 2023 10.4143/crt.2021.1527 A Phase II Study of Preoperative Chemoradiotherapy with Capecitabine Plus Simvastatin in Patients with Locally Advanced Rectal Cancer Jo, H; Kim, ST; Lee, JY; Park, SH; Park, JO; Park, YS; Lim, HY; Il Yu, J; Park, HC; Choi, DH; Park, Y; Cho, YB; Huh, JW; Yun, SH; Kim, HC; Lee, WY; Kang, WK
    View PubMed
  • LANCET ONCOL 2022 Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial Powles, T; Tomczak, P; Park, SH; Venugopal, B; Ferguson, T; Symeonides, SN; Hajek, J; Gurney, H; Chang, YH; Lee, JL; Sarwar, N; Thiery-Vuillemin, A; Gross-Goupil, M; Mahave, M; Haas, NB; Sawrycki, P; Burgents, JE; Xu, L; Imai, K; Quinn, DI; Choueiri, TK
    View PubMed
  • BIOMEDICINES 2022 10.3390/biomedicines10082005 Subsequent Systemic Therapy following Platinum and Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma Hong, J; Sung, HH; Jeong, BC; Park, SH
    View PubMed
  • EUR J CANCER 2022 10.1016/j.ejca.2022.07.014 Enfortumab vedotin-related pneumonitis is more common than expected and could lead to acute respiratory failure Yoon, S; Shin, SJ; Kim, HC; Kim, YS; Lee, HJ; Keam, B; Choi, YJ; Kim, YJ; Park, I; Park, SH; Lee, JL
    View PubMed
  • CLIN ONCOL-UK 2022 10.1016/j.clon.2022.02.011 A Comparison of Folinic Acid, Fluorouracil and Irinotecan (FOLFIRI) plus Bevacizumab and FOLFIRI plus Aflibercept as Second-line Treatment for Metastatic Colorectal Cancer Jo, H; Lee, MS; Lee, YP; Kim, H; Hong, JY; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, ST
    View PubMed
  • CANCER RES TREAT 2022 10.4143/crt.2021.1019 A Single-Arm, Prospective, Phase II Study of Cisplatin Plus Weekly Docetaxel as First-Line Therapy in Patients with Metastatic or Recurrent Salivary Gland Cancer Kim, HR; Lee, SJ; Park, S; Jung, HA; Lee, SH; Jeong, HS; Chung, MK; Ahn, MJ
    View PubMed
  • BIOMEDICINES 2022 10.3390/biomedicines10071565 Clinical Significance of Preoperative Hematological Parameters in Patients with D2-Resected, Node-Positive Stomach Cancer Park, JS; Yu, JI; Lim, DH; Nam, H; Kim, YI; Lee, J; Kang, WK; Park, SH; Kim, ST; Hong, JY; Sohn, TS; Lee, JH; An, JY; Choi, MG; Bae, JM
    View PubMed
  • CANCER RES TREAT 2022 10.4143/crt.2021.854 Genomic Sequencing for Bladder Urothelial Carcinoma and Its Clinical Implications for Immunotherapy Kim, R; Hong, JY; Lee, J; Kwon, GY; Jeong, BC; Park, SH
    View PubMed
  • CURR PROB CANCER 2022 10.1016/j.currproblcancer.2022.100848 Prognostic model in patients with metastatic urothelial carcinoma receiving immune checkpoint inhibitors after platinum failure Park, JH; Park, I; Kim, IH; Hur, JY; Hwang, I; Kim, C; Kim, HJ; Maeng, CH; Park, K; Lee, MY; Lee, HJ; Jung, JY; Keam, B; Park, SH; Lee, JL
    View PubMed
  • CANCERS 2022 10.3390/cancers14102354 Molecular Subtypes Based on Genomic and Transcriptomic Features Correlate with the Responsiveness to Immune Checkpoint Inhibitors in Metastatic Clear Cell Renal Cell Carcinoma Jee, B; Seo, E; Park, K; Kim, YR; Byeon, SJ; Lee, SM; Chung, JH; Song, W; Sung, HH; Jeon, HG; Jeong, BC; Seo, SI; Jeon, SS; Lee, HM; Park, SH; Park, WY; Kang, MY
    View PubMed
  • FRONT ONCOL 2022 10.3389/fonc.2022.874385 A Retrospective Study of First-Line Therapy Involving Immune Checkpoint Inhibitors in Patients With Poor Risk Metastatic Renal Cell Carcinoma Jo, H; Hong, J; Kim, H; Kim, HR; Kwon, GY; Kang, KA; Park, SY; Kim, CK; Park, BK; Chung, JH; Song, W; Kang, M; Sung, HH; Jeon, HG; Jeong, BC; Seo, SI; Jeon, SS; Lee, HM; Park, SH
    View PubMed
  • FUTURE ONCOL 2022 10.2217/fon-2021-1631 Plain language summary of results from the JAVELIN Bladder 100 study: avelumab maintenance treatment for advanced urothelial cancer Powles, T; Park, SH; Voog, E; Caserta, C; Valderrama, BP; Gurney, H; Kalofonos, H; Radulovic, S; Demey, W; Ullen, A; Loriot, Y; Sridhar, SS; Tsuchiya, N; Kopyltsov, E; Sternberg, CN; Bellmunt, J; Aragon-Ching, JB; Petrylak, DP; Laliberte, RJ; Huang, B; Costa, N; Blake-Haskins, JA; Grivas, P
    View PubMed
  • J ONCOL 2022 10.1155/2022/9714570 Incidence of FGFR2 Amplification and FGFR2 Fusion in Patients with Metastatic Cancer Using Clinical Sequencing Hyung, S; Han, B; Jung, J; Kim, ST; Hong, JY; Park, SH; Zang, DY; Park, JO; Park, YS; Kim, KM; Kang, WK; Lee, J
    View PubMed
  • INVESTIG CLIN UROL 2022 10.4111/icu.20210407 Neoadjuvant chemotherapy with gemcitabine and cisplatin followed by selective bladder preservation chemoradiotherapy in muscle-invasive urothelial carcinoma of bladder Sung, HH; Kim, H; Kim, R; Kim, CK; Kwon, GY; Park, W; Song, W; Jeong, BC; Park, SH
    View PubMed
  • LANCET ONCOL 2022 10.1016/S1470-2045(21)00660-4 Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study Siefker-Radtke, AO; Necchi, A; Park, SH; Garcia-Donas, J; Huddart, RA; Burgess, EF; Fleming, MT; Kalebasty, AR; Mellado, B; Varlamov, S; Joshi, M; Duran, I; Tagawa, ST; Zakharia, Y; Akapame, S; Santiago-Walker, AE; Monga, M; O'Hagan, A; Loriot, Y
    View PubMed
  • GASTRIC CANCER 2022 10.1007/s10120-021-01276-4 Ramucirumab plus paclitaxel as a second-line treatment in HER2-positive gastric cancer: subgroup analysis of a nationwide, real-world study in Korea (KCSG-ST19-16) Kim, BJ; Jee, HJ; Rha, SY; Han, HS; Ryu, MH; Park, SH; Kim, JG; Bae, WK; Lee, KW; Oh, DY; Byun, JH; Kim, DS; Suh, YJ; An, H; Zang, DY
    View PubMed
  • CANCERS 2021 10.3390/cancers13246345 Prognostic Impact of Sarcopenia in Patients with Metastatic Hormone-Sensitive Prostate Cancer Lee, JH; Jee, BA; Kim, JH; Bae, H; Chung, JH; Song, W; Sung, HH; Jeon, HG; Jeong, BC; Seo, SI; Jeon, SS; Lee, HM; Park, SH; Kang, M
    View PubMed
  • BMC CANCER 2021 10.1186/s12885-021-09018-6 A prospective phase-II trial of biweekly docetaxel plus androgen deprivation therapy in patients with previously-untreated metastatic castration-naive prostate cancer Byeon, S; Kim, H; Jeon, HG; Il Seo, S; Jeon, SS; Lee, HM; Il Lee, S; Park, SH
    View PubMed
  • THER ADV MED ONCOL 2021 10.1177/17588359211042812 Ramucirumab plus paclitaxel as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma: a nationwide real-world outcomes in Korea study (KCSG-ST19-16) Han, HS; Kim, BJ; Jee, HJ; Ryu, MH; Park, SH; Rha, SY; Kim, JG; Bae, WK; Lee, KW; Oh, DY; Kim, IH; Sym, SJ; Oh, SY; Kim, HS; Byun, JH; Kim, DS; Suh, YJ; An, H; Zang, DY
    View PubMed
  • CANCER MED-US 2021 10.1002/cam4.4259 Reducing tumor invasiveness by ramucirumab and TGF-beta receptor kinase inhibitor in a diffuse-type gastric cancer patient-derived cell model Lee, SY; Byeon, S; Ko, J; Hyung, S; Lee, IK; Li Jeon, N; Hong, JY; Kim, ST; Park, SH; Lee, J
    View PubMed
  • J CANCER RES CLIN 2021 10.1007/s00432-021-03781-6 The prevalence of homologous recombination deficiency (HRD) in various solid tumors and the role of HRD as a single biomarker to immune checkpoint inhibitors Kim, H; Ahn, S; Kim, H; Hong, JY; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, KM; Kim, ST
    View PubMed
  • CLIN CANCER RES 2021 10.1158/1078-0432.CCR-21-0251 Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer Kim, ST; Smith, SA; Mortimer, P; Loembe, AB; Cho, H; Kim, KM; Smith, C; Willis, S; Irurzun-Arana, I; Berges, A; Hong, JY; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kozarewa, I; Pierce, AJ; Dean, E; Lee, J
    View PubMed
  • NEW ENGL J MED 2021 10.1056/NEJMoa2106391 Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma Choueiri, TK; Tomczak, P; Park, SH; Venugopal, B; Ferguson, T; Chang, YH; Hajek, J; Symeonides, SN; Lee, JL; Sarwar, N; Thiery-Vuillemin, A; Gross-Goupil, M; Mahave, M; Haas, NB; Sawrycki, P; Gurney, H; Chevreau, C; Melichar, B; Kopyltsov, E; Alva, A; Burke, JM; Doshi, G; Topart, D; Oudard, S; Hammers, H; Kitamura, H; Bedke, J; Perini, RF; Zhang, P; Imai, K; Willemann-Rogerio, J; Quinn, DI; Powles, T
    View PubMed
  • CANCER RES TREAT 2021 10.4143/crt.2020.1066 Clinical Experience of Male Primary Choriocarcinoma at the Samsung Medical Center Ji, YS; Park, SH
    View PubMed
  • LANCET ONCOL 2021 10.1016/S1470-2045(21)00094-2 Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV-201): a multicentre, single-arm, phase 2 trial Yu1, EY; Petrylak, DP; O'Donnell, PH; Lee, JL; van der Heijden, MS; Loriot, Y; Stein, MN; Necchi, A; Kojima, T; Harrison, MR; Park, SH; Quinn, DI; Heath, EI; Rosenberg, JE; Steinberg, J; Liang, SY; Trowbridge, J; Campbell, M; McGregor, B; Balar, AV
    View PubMed
  • J PERS MED 2021 10.3390/jpm11060575 Detection of Aberrant Glycosylation of Serum Haptoglobin for Gastric Cancer Diagnosis Using a Middle-Up-Down Glycoproteome Platform Jeong1, S; Kim, U; Oh, M; Nam, J; Park, S; Choi, Y; Lee, D; Kim, J; An, H
    View PubMed
  • NEW ENGL J MED 2021 10.1056/NEJMoa2034442 Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma Bajorin1, DF; Witjes, JA; Gschwend, JE; Schenker, M; Valderrama, BP; Tomita, Y; Bamias, A; Lebret, T; Shariat, SF; Park, SH; Ye, D; Agerbaek, M; Enting, D; McDermott, R; Gajate, P; Peer, A; Milowsky, MI; Nosov, A; Antonio, JN; Tupikowski, K; Toms, L; Fischer, BS; Qureshi, A; Collette, S; Unsal-Kacmaz, K; Broughton, E; Zardavas, D; Koon, HB; Galsky, MD
    View PubMed
  • KOREAN J INTERN MED 2021 10.3904/kjim.2020.213 2020 Korean guidelines for the management of metastatic prostate cancer Kim1, IH; Shin, SJ; Kang, BW; Kang, J; Kim, D; Kim, M; Kim, JY; Kim, CK; Kim, HJ; Maeng, CH; Park, K; Park, I; Bae, WK; Sohn, BS; Lee, MY; Lee, JL; Lee, J; Lim, ST; Lim, JH; Chang, H; Jung, JY; Choi, YJ; Kim, YS; Cho, J; Joung, JY; Park, SH; Lee, HJ
    View PubMed
  • ONCOLOGY-BASEL 2021 10.1159/000514404 Programmed Death Ligand 1 Expression as a Prognostic Marker in Patients with Advanced Biliary Tract Cancer Kim1, H; Kim, J; Byeon, S; Jang, KT; Hong, JY; Lee, JY; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, ST
    View PubMed
  • ANN ONCOL 2021 10.1016/j.annonc.2020.11.017 A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial Park1, SH; Lim, DH; Sohn, TS; Lee, J; Zang, DY; Kim, ST; Kang, JH; Oh, SY; Hwang, IG; Ji, JH; Shin, DB; Yu, JI; Kim, KM; An, JY; Choi, MG; Lee, JH; Kim, S; Hong, JY; Park, JO; Park, YS; Lim, HY; Bae, JM; Kang, WK
    View PubMed
  • THER ADV MED ONCOL 2021 10.1177/1758835921992992 Clinical sequencing to assess tumor mutational burden as a useful biomarker to immunotherapy in various solid tumors Kim1, H; Hong, JY; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, KM; Kim, ST
    View PubMed
  • CANCERS 2021 10.3390/cancers13010059 Impact of Radiotherapy on Kidney Function among Patients Who Received Adjuvant Treatment for Gastric Cancer: Logistic and Linear Regression Analyses Park1, JS; Il Yu, J; Lim, D; Nam, H; Kim, YI; Lee, J; Kang, WK; Park, SH; Kim, ST; Hong, JY; Sohn, TS; Lee, JH; An, JY; Choi, MG; Bae, JM
    View PubMed
  • J CANCER 2021 10.7150/jca.49176 Prognostic Factors of Survival with Aflibercept and FOLFIRI (fluorouracil, leucovorin, irinotecan) as Second-line Therapy for Patients with Metastatic Colorectal Cancer Kim1, J; Kim, H; Hong, JY; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, ST
    View PubMed
  • LANCET ONCOL 2020 10.1016/S1470-2045(20)30541-6 Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE) a randomised, open-label, multicentre, phase 3 trial Powles1, T; van der Heijden, MS; Castellano, D; Galsky, MD; Loriot, Y; Petrylak, DP; Ogawa, O; Park, SN; Lee, JL; De Giorgi, U; Bogemann, M; Bamias, A; Eigl, BJ; Gurney, H; Mukherjee, SD; Fradet, Y; Skoneczna, I; Tsiatas, M; Novikov, A; Suarez, C; Fay, AP; Duran, I; Necchi, A; Wildsmith, S; He, P; Angra, N; Gupta, AK; Levin, W; Bellmunt, J
    View PubMed
  • THER ADV MED ONCOL 2020 10.1177/1758835920965842 Clinical and molecular distinctions in patients with refractory colon cancer who benefit from regorafenib treatment Lee1, MS; Cho, HJ; Hong, JY; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Cho, YB; Kim, ST
    View PubMed
  • INVESTIG CLIN UROL 2020 10.4111/icu.20200214 Docetaxel rechallenge in metastatic castration-resistant prostate cancer A retrospective, single-center study Byeon1, S; Kim, H; Kim, J; Kwon, M; Hur, JY; Jeon, HG; Jeon, SS; Lee, HM; Park, SH
    View PubMed
  • CANCER SCI 2020 10.1111/cas.14681 Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinoma Ye1, DW; Liu, JY; Zhou, AP; Zou, Q; Li, HZ; Fu, C; Hu, HL; Huang, J; Zhu, SX; Jin, J; Ma, LL; Guo, JM; Xiao, J; Park, SH; Zhang, DH; Qiu, XS; Bao, YY; Zhang, LL; Shen, W; Bi, F
    View PubMed
  • RADIOTHER ONCOL 2020 10.1016/j.radonc.2020.07.043 Effect of baseline sarcopenia on adjuvant treatment for D2 dissected gastric cancer Analysis of the ARTIST phase III trial Yu1, JI; Choi, C; Lee, J; Kang, WK; Park, SH; Kim, ST; Hong, JY; Kim, S; Sohn, TS; Lee, JH; An, JY; Choi, MG; Bae, JM; Kim, KM; Han, H; Kim, K; Nam, H; Lim, DH
    View PubMed
  • CLIN CANCER RES 2020 10.1158/1078-0432.CCR-20-1246 A Phase II Trial of Tipifarnib for Patients with Previously Treated, Metastatic Urothelial Carcinoma Harboring HRAS Mutations Lee1, HW; Sa, JK; Gualberto, A; Scholz, C; Sung, HH; Jeong, BC; Choi, HY; Kwon, GY; Park, SH
    View PubMed
  • ASIA-PAC J CLIN ONCO 2020 10.1111/ajco.13479 Radium-223 in Asian patients with castration-resistant prostate cancer with symptomatic bone metastases A single-arm phase 3 study Zhou1, T; Zhou, FJ; Guo, JM; Shi, HC; Yao, XD; Guo, HQ; Yuan, J; Tian, Y; Zhang, XD; Wang, SX; Jiang, YG; Zou, Q; Zhou, DQ; Li, HZ; Li, F; Lee, JL; Chen, CH; Park, SH; Ng, QS; Ma, JH; Zheng, R; Ding, Q; Liu, XD; Li, R; Krissel, H; Wagner, VJ; Sun, YH
    View PubMed
  • J CANCER 2020 10.7150/jca.48062 Prognostic Impact of Bone Metastasis on Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma Treated by First Line Tyrosine Kinase Inhibitors A Propensity-Score Matching Analysis Kang1, M; Choi, J; Kim, J; Sung, HH; Jeon, HG; Jeong, BC; Jeon, SS; Lee, HM; Park, SH; Song, C; Seo, SI
    View PubMed
  • NEW ENGL J MED 2020 10.1056/NEJMoa2002788 Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma Powles1, T; Park, SH; Voog, E; Caserta, C; Valderrama, BP; Gurney, H; Kalofonos, H; Radulovic, S; Demey, W; Ullen, A; Loriot, Y; Sridhar, SS; Tsuchiya, N; Kopyltsov, E; Sternberg, CN; Bellmunt, J; Aragon-Ching, JB; Petrylak, DP; Laliberte, R; Wang, J; Huang, B; Davis, C; Fowst, C; Costa, N; Blake-Haskins, JA; di Pietro, A; Grivas, P
    View PubMed
  • LANCET ONCOL 2020 10.1016/S1470-2045(20)30326-0 Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05) a single-arm, phase 1b-2 trial Catenacci1, DVT; Kang, YK; Park, H; Uronis, HE; Lee, KW; Ng, MCH; Enzinger, PC; Park, SH; Gold, PJ; Lacy, J; Hochster, HS; Oh, SC; Kim, YH; Marrone, KA; Kelly, RJ; Juergens, RA; Kim, JG; Bendell, JC; Alcindor, T; Sym, SJ; Song, EK; Chee, CE; Chao, Y; Kim, S; Lockhart, AC; Knutson, KL; Yen, J; Franovic, A; Nordstrom, JL; Li, D; Wigginton, J; Davidson-Moncada, JK; Rosales, MK; Bang, YJ
    View PubMed
  • LANCET ONCOL 2020 10.1016/S1470-2045(20)30315-6 S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin as first-line therapy in patients with advanced gastric cancer (SOLAR) a randomised, open-label, phase 3 trial Kang1, YK; Chin, K; Chung, HC; Kadowaki, S; Oh, SC; Nakayama, N; Lee, KW; Hara, H; Chung, IJ; Tsuda, M; Park, SH; Hosaka, H; Hironaka, S; Miyata, Y; Ryu, MH; Baba, H; Hyodo, I; Bang, YJ; Boku, N
    View PubMed
  • THER ADV MED ONCOL 2020 10.1177/1758835920926796 First-in-human phase I trial of anti-hepatocyte growth factor antibody (YYB101) in refractory solid tumor patients Kim1, ST; Hong, JY; Park, SH; Park, JO; Park, YW; Park, N; Lee, H; Hong, SH; Lee, SJ; Song, SW; Kim, K; Park, YS; Lim, HY; Kang, WK; Nam, H; Lee, JW; Park, K; Kim, KM; Lee, J
    View PubMed
  • LANCET 2020 10.1016/S0140-6736(20)30230-0 Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial Galsky1, MD; Arija, JAA; Bamias, A; Davis, ID; De Santis, M; Kikuchi, E; Garcia-del-Muro, X; De Giorgi, U; Mencinger, M; Izumi, K; Panni, S; Gumus, M; Ozguroglu, M; Kalebasty, AR; Park, SH; Alekseev, B; Schutz, FA; Li, JR; Ye, DW; Vogelzang, NJ; Bernhard, S; Tayama, D; Mariathasan, S; Mecke, A; Thastrom, A; Grande, E
    View PubMed
  • Transl Cancer Res 2020 10.21037/tcr-19-1876 Claudin 18.2 expression in various tumor types and its role as a potential target in advanced gastric cancer Hong1, JY; An, JY; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kim, KM; Kang, WK; Kim, ST
    View PubMed
  • Genome Med 2020 10.1186/s13073-020-00741-6 Single-cell RNA sequencing reveals the tumor microenvironment and facilitates strategic choices to circumvent treatment failure in a chemorefractory bladder cancer patient Lee1, HW; Chung, W; Lee, HO; Jeong, D; Jo, A; Lim, JE; Hong, JH; Nam, DH; Jeong, BC; Park, SH; Joo, KM; Park, WY
    View PubMed
  • TARGET ONCOL 2020 10.1007/s11523-020-00706-0 Use of Gefitinib in EGFR-Amplified Refractory Solid Tumors: An Open-Label, Single-Arm, Single-Center Prospective Pilot Study Byeon1, S; Hong, JY; Lee, J; Nam, DH; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, ST
    View PubMed
  • PATHOL RES PRACT 2020 10.1016/j.prp.2020.152881 High PD-L1 expression in gastric cancer (GC) patients and correlation with molecular features Liu1, XQ; Choi, MG; Kim, K; Kim, KM; Kim, ST; Park, SH; Cristescu, R; Peter, S; Lee, J
    View PubMed
  • JAMA-J AM MED ASSOC 2020 10.1001/jama.2020.1707 Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas The ANNOUNCE Randomized Clinical Trial Tap1, WD; Wagner, AJ; Schoffski, P; Martin-Broto, J; Krarup-Hansen, A; Ganjoo, KN; Yen, CC; Razak, AAR; Spira, A; Kawai, A; Le Cesne, A; Van Tine, BA; Naito, Y; Park, SH; Fedenko, A; Papai, Z; Soldatenkova, V; Shahir, A; Mo, G; Wright, J; Jones, RL
    View PubMed
  • INT J MOL SCI 2020 10.3390/ijms21082825 Synergistic Effects of Combination Therapy with AKT and mTOR Inhibitors on Bladder Cancer Cells Kim1, H; Lee, SJ; Lee, IK; Min, SC; Sung, HH; Jeong, BC; Lee, J; Park, SH
    View PubMed
  • CANCERS 2020 10.3390/cancers12040943 Outcomes of Radiotherapy for Mesenchymal and Non-Mesenchymal Subtypes of Gastric Cancer Yu1, JI; Park, HC; Lee, J; Choi, C; Kang, WK; Park, SH; Kim, ST; Sohn, TS; Lee, JH; An, JY; Choi, MG; Bae, JM; Kim, KM; Han, H; Kim, K; Kim, S; Lim, DH
    View PubMed
  • ESMO OPEN 2020 10.1136/esmoopen-2020-000670 Clinical scoring system for the prediction of survival of patients with advanced gastric cancer Kim1, J; Hong, JY; Kim, ST; Park, SH; Jekal, SY; Choi, JS; Chang, DK; Kang, WK; Seo, SW; Lee, J
    View PubMed
  • PATHOL RES PRACT 2020 10.1016/j.prp.2020.152820 TPK1 as a predictive marker for the anti-tumour effects of simvastatin in gastric cancer Hong1, JY; Kim, HJ; Kim, K; Hong, J; Kim, JE; Byeon, SJ; Lee, IK; Kim, KM; Shim, M; Park, SH; Park, JO; Park, YS; Lim, HY; Kim, ST; Lee, J; Kang, WK
    View PubMed
  • Front Oncol 2020 10.3389/fonc.2020.00314 Tumor Mutational Burden Determined by Panel Sequencing Predicts Survival After Immunotherapy in Patients With Advanced Gastric Cancer Kim1, J; Kim, B; Kang, SY; Heo, YJ; Park, SH; Kim, ST; Kang, WK; Lee, J; Kim, KM
    View PubMed
  • Genome Med 2020 10.1186/s13073-020-0717-8 Comprehensive pharmacogenomic characterization of gastric cancer Sa1, JK; Hong, JY; Lee, IK; Kim, JS; Sim, MH; Kim, HJ; An, JY; Sohn, TS; Lee, JH; Bae, JM; Kim, S; Kim, KM; Kim, ST; Park, SH; Park, JO; Lim, HY; Kang, WK; Her, NG; Lee, Y; Cho, HJ; Shin, YJ; Kim, M; Koo, H; Kim, M; Seo, YJ; Kim, JY; Choi, MG; Nam, DH; Lee, J
    View PubMed
  • J CLIN ONCOL 2020 10.1200/JCO.19.01638 Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study Antonarakis1, ES; Piulats, JM; Gross-Goupil, M; Goh, J; Ojamaa, K; Hoimes, CJ; Vaishampayan, U; Berger, R; Sezer, A; Alanko, T; de Wit, R; Li, CD; Omlin, A; Procopio, G; Fukasawa, S; Tabata, KI; Park, SH; Feyerabend, S; Drake, CG; Wu, HY; Qiu, P; Kim, J; Poehlein, C; de Bono, JS
    View PubMed
  • J ONCOL 2020 10.1155/2020/4659062 Detection of Fusion Genes Using a Targeted RNA Sequencing Panel in Gastrointestinal and Rare Cancers Lee1, SJ; Hong, JY; Kim, K; Kim, KM; Kang, SY; Lee, T; Kim, ST; Park, SH; Park, YS; Lim, HY; Kang, WK; Lee, J; Park, JO
    View PubMed
  • CLIN GENITOURIN CANC 2019 10.1016/j.clgc.2019.07.014 Novel Predictive Models of Early Death Less Than 1 Year in Patients With Metastatic Renal Cell Carcinoma After Treatment With First-line Tyrosine Kinase Inhibitors Shin1, SJ; Kim, T; Sung, HH; Jeon, HG; Jeong, BC; Park, SH; Jeon, SS; Lee, HM; Choi, HY; Seo, SI; Kang, M
    View PubMed
  • INT J CANCER 2019 10.1002/ijc.32228 Bridging genomics and phenomics of gastric carcinoma Cho1, J; Ahn, S; Son, DS; Kim, NKD; Lee, KW; Kim, S; Lee, J; Park, SH; Park, JO; Kang, WK; An, JY; Choi, MG; Lee, JH; Sohn, TS; Bae, JM; Kim, S; Kim, KM
    View PubMed
  • GASTRIC CANCER 2019 10.1007/s10120-019-00958-4 A phase I/II study of poziotinib combined with paclitaxel and trastuzumab in patients with HER2-positive advanced gastric cancer Kim1, TY; Han, HS; Lee, KW; Zang, DY; Rha, SY; Park, YL; Kim, JS; Lee, KH; Park, SH; Song, EK; Jung, SA; Lee, N; Kim, YH; Cho, JY; Bang, YJ
    View PubMed
  • Front Oncol 2019 10.3389/fonc.2019.01327 Systematic Evaluation of Gastric Tumor Cell Index and Two-Drug Combination Therapy via 3-Dimensional High-Throughput Drug Screening Lim1, SH; Sa, JK; Lee, DW; Kim, J; Kim, ST; Park, SH; Ku, B; Park, JO; Park, YS; Lim, H; Kang, WK; Nam, DH; Lee, J
    View PubMed
  • ANTICANCER RES 2019 10.21873/anticanres.13785 Clinical Outcomes and the Role of Adjuvant Concurrent Chemoradiation Therapy in D2-resected LN-positive Young Patients (<= 45 Years) With Gastric Cancer Yu1, JI; Lim, DH; Lee, J; Kang, WK; Park, SH; Park, JO; Lim, HY; Kim, ST; Kim, S; Sohn, TS; Lee, JH; An, JY; Choi, MG; Bae, JM; Kim, HS; Ahn, S
    View PubMed
  • J IMMUNOTHER 2019 10.1097/CJI.0000000000000283 LAG3 in Solid Tumors as a Potential Novel Immunotherapy Target Lee1, SJ; Byeon, SJ; Lee, J; Park, SH; Park, JO; Park, YS; Kang, WK; Lim, HY; Kim, KM; Kim, ST
    View PubMed
  • CANCER DISCOV 2019 10.1158/2159-8290.CD-19-0442 Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial Lee1, J; Kim, ST; Kim, K; Lee, H; Kozarewa, I; Mortimer, PGS; Odegaard, JI; Harrington, EA; Lee, J; Lee, T; Oh, SY; Kang, JH; Kim, JH; Kim, Y; Ji, JH; Kim, YS; Lee, KE; Kim, J; Sohn, TS; An, JY; Choi, MG; Lee, JH; Bae, JM; Kim, S; Kim, JJ; Min, YW; Min, BH; Kim, NKD; Luke, S; Kim, YH; Hong, JY; Park, SH; Park, JO; Park, YS; Lim, HY; Talasaz, A; Hollingsworth, SJ; Kim, KM; Kang, WK
    View PubMed
  • LANCET ONCOL 2019 10.1016/S1470-2045(19)30412-7 Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study Schuler1, M; Cho, BC; Sayehli, CM; Navarro, A; Soo, RA; Richly, H; Cassier, PA; Tai, D; Penel, N; Nagoya, L; Park, SH; Schostak, M; Gajate, P; Cathomas, R; Rajagopalan, P; Grevel, J; Bender, S; Boix, O; Nogai, H; Ocker, M; Eflinghaus, P; Joerger, M
    View PubMed
  • CANCER RES TREAT 2019 10.4143/crt.2018.604 Atezolizumab in Patients with Pretreated Urothelial Cancer: A Korean Single-Center, Retrospective Study Hur1, JY; Kim, Y; Kwon, GY; Kang, M; Sung, HH; Jean, HG; Jeong, BC; Seo, SI; Jean, SS; Lee, HM; Lee, SJ; Park, SH
    View PubMed
  • Transl Cancer Res 2019 10.21037/tcr.2019.09.27 Detection of circulating tumor cells (CTCs) in cerebrospinal fluid of a patient with HER2-overexpressing gastric cancer and single cell analysis of intra-patient heterogeneity of CTCs Cho1, JH; Kim, SY; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, ST
    View PubMed
  • Cancer Med 2019 10.1002/cam4.2446 Comparative effectiveness of palliative chemotherapy versus neoadjuvant chemotherapy followed by radical cystectomy versus cystectomy followed by adjuvant chemotherapy versus cystectomy for regional node-positive bladder cancer: A retrospective analysis: KCSG GU 17-03 Bae1, WK; Lee, HJ; Park, SH; Kim, JH; Kim, HJ; Maeng, CH; Park, I; Sohn, BS; Kim, JA; Lee, KH; Lim, D; Chang, H; Kim, SM; Kim, HY; Song, H; Lim, S; Byun, JH; Jung, HA
    View PubMed
  • NEW ENGL J MED 2019 10.1056/NEJMoa1817323 Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma Loriot1, Y; Necchi, A; Park, SH; Garcia-Donas, J; Huddart, R; Burgess, E; Fleming, M; Rezazadeh, A; Mellado, B; Varlamov, S; Joshi, M; Duran, I; Tagawa, ST; Zakharia, Y; Zhong, B; Stuyckens, K; Santiago-Walker, A; De Porre, P; O'Hagan, A; Avadhani, A; Siefker-Radtke, AO
    View PubMed
  • CANCER RES TREAT 2019 10.4143/crt.2018.401 Comparison of the 7th and the 8th AJCC Staging System for Non-metastatic D2-Resected Lymph Node-Positive Gastric Cancer Treated with Different Adjuvant Protocols Yu1, JI; Lim, D; Lee, J; Kang, WK; Park, SH; Park, JO; Park, YS; Lim, HY; Kim, ST; Lee, SJ; Kim, S; Sohn, TS; Lee, JH; An, JY; Choi, MG; Rae, JM; Yoo, H; Kim, K
    View PubMed
  • Am J Transl Res 2019 Neutralizing antibody to FGFR2 can act as a selective biomarker and potential therapeutic agent for gastric cancer with FGFR2 amplification Kim1, ST; Lee, IK; Rom, E; Sirkis, R; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, KM; Yayon, A; Lee, J
    View PubMed
  • J Cancer 2019 10.7150/jca.30355 The impact of primary tumor site on outcomes of treatment with etoposide and cisplatin in grade 3 gastroenteropancreatic neuroendocrine carcinoma Yoon1, SE; Kim, JH; Lee, SJ; Lee, J; Park, SH; Park, JO; Lim, HY; Kang, WK; Park, YS; Kim, ST
    View PubMed
  • J Cancer 2019 10.7150/jca.30257 High delta-like ligand 4 expression correlates with a poor clinical outcome in gastric cancer Kim1, Y; Byeon, SJ; Hur, J; Lee, K; Kim, D; Ahn, JH; Lee, SH; You, WK; Kim, ST; Park, SH; Kang, WK; Kim, KM; Lee, J
    View PubMed
  • ONCOLOGY-BASEL 2019 10.1159/000499628 Prognostic Impact of Microsatellite Instability in Asian Gastric Cancer Patients Enrolled in the ARTIST Trial Miceli1, R; An, J; Di Bartolomeo, M; Morano, F; Kim, ST; Park, SH; Choi, MG; Lee, JH; Raimondi, A; Fuca, G; Sohn, TS; Bae, JM; Kim, S; Lim, DH; Kang, WK; Kim, KM; Pietrantonio, F; Lee, J
    View PubMed
  • BMC UROL 2019 10.1186/s12894-019-0463-7 A retrospective feasibility study of biweekly docetaxel in patients with high-risk metastatic castration-naive prostate cancer Yoon1, SE; Kim, Y; Cho, J; Kang, M; Sung, HH; Jeon, HG; Jeong, BC; Seo, SI; Jeon, SS; Lee, HM; Choi, HY; Lee, SJ; Park, SH
    View PubMed
  • J ONCOL 2019 10.1155/2019/8736163 Risk Prediction for Contrast-Induced Nephropathy in Cancer Patients Undergoing Computed Tomography under Preventive Measures Jeon1, J; Kim, S; Yoo, H; Kim, K; Kim, Y; Park, S; Jang, HR; Kim, DK; Huh, W; Kim, YG; Kim, DJ; Oh, HY; Lee, JE
    View PubMed
  • TRANSL ONCOL 2019 10.1016/j.tranon.2018.12.009 Combination of Docetaxel Plus Savolitinib in Refractory Cancer Patients: A Report on Phase I Trial Kim1, ST; Lee, S; Park, M; Park, SH; Park, JO; Lim, HY; Park, YS; Kang, WK; Gangolli, EA; Shin, H; Kim, KM; Hollingsworth, SJ; Mortimer, PGS; Lee, J
    View PubMed
  • CANCER RES TREAT 2019 10.4143/crt.2018.151 Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in Korea Byeon1, S; Kim, Y; Lim, SW; Cho, JH; Park, S; Lee, J; Sun, JM; Choi, YL; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • J Cancer 2019 10.7150/jca.29106 The Impact of Primary Tumor Sidedness on the Effect of Regorafenib in Refractory Metastatic Colorectal Cancer Yoon1, SE; Lee, SJ; Lee, J; Park, SH; Park, JO; Lim, HY; Kang, WK; Park, YS; Kim, ST
    View PubMed
  • CANCER CHEMOTH PHARM 2019 10.1007/s00280-018-3753-y Safety and efficacy of trastuzumab administered as a 30-min infusion in patients with HER2-positive advanced gastric cancer Oh1, SY; Lee, S; Huh, SJ; Lee, J; Kim, ST; Park, SH; Lim, HY; Kang, WK; Kang, BW; Kim, JG; Lee, HJ; Kim, JH; Kang, JH; Kim, H
    View PubMed
  • CANCERS 2019 10.3390/cancers11020187 SOURCE: A Registry-Based Prediction Model for Overall Survival in Patients with Metastatic Oesophageal or Gastric Cancer van den Boom1, HG; Abu-Hanna, A; ter Veer, E; van Kleef, JJ; Lordick, F; Stahl, M; Ajani, JA; Guimbaud, R; Park, SH; Dutton, SJ; Bang, YJ; Boku, N; Mohammad, NH; Sprangers, MAG; Verhoeven, RHA; Zwinderman, AH; van Oijen, MGH; van Laarhoven, HWM
    View PubMed
  • Oncoimmunology 2019 10.1080/2162402X.2018.1544442 PD-L1 and immune infiltrates are differentially expressed in distinct subgroups of gastric cancer Angell1, HK; Lee, J; Kim, KM; Kim, K; Kim, ST; Park, SH; Kang, WK; Sharpe, A; Ogden, J; Davenport, A; Hodgson, DR; Barrett, JC; Kilgour, E
    View PubMed
  • OncoTargets and therapy 2019 10.2147/OTT.S187621 The use of regorafenib for patients with refractory metastatic colorectal cancer in clinical practice Yoon1, SE; Lee, SJ; Lee, J; Park, SH; Park, JO; Lim, HY; Kang, WK; Park, YS; Kim, ST
    View PubMed
  • ONCOLOGY-BASEL 2018 10.1159/000491753 Estimating Survival Probabilities of Advanced Gastric Cancer Patients in the Second-Line Setting: The Gastric Life Nomogram Pietrantonio1, F; Barretta, F; Fanotto, V; Park, SH; Morano, F; Fuca, G; Niger, M; Prisciandaro, M; Silvestris, N; Bergamo, F; Fornaro, L; Bordonaro, R; Rimassa, L; Santini, D; Tomasello, G; Antonuzzo, L; Noventa, S; Avallone, A; Leone, F; Faloppi, L; Di Donato, S; de Braud, F; Lee, J; De Vita, F; Di Bartolomeo, M; Miceli, R; Aprile, G
    View PubMed
  • J Gastric Cancer 2018 10.5230/jgc.2018.18.e34 Adjuvant Chemotherapy with or without Concurrent Radiotherapy for Patients with Stage IB Gastric Cancer: a Subgroup Analysis of the Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) Phase III Trial Kim1, Y; Kim, KM; Choi, MG; Lee, JH; Sohn, TS; Bae, JM; Kim, S; Lee, SJ; Kim, ST; Lee, J; Park, JO; Park, YS; Lim, HY; Kang, WK; Park, SH
    View PubMed
  • RADIOTHER ONCOL 2018 10.1016/j.radonc.2018.07.002 Necessity of adjuvant concurrent chemo-radiotherapy in D2-resected LN-positive gastric cancer Yu1, JI; Lim, DH; Lee, J; Kang, WK; Park, SH; Park, JO; Park, YS; Lim, HY; Kim, ST; Lee, SJ; Kim, S; Sohn, TS; Lee, JH; An, JY; Choi, MG; Bae, JM; Kim, HS; Ahn, S
    View PubMed
  • BMC CANCER 2018 10.1186/s12885-018-4995-0 Triptolide as a novel agent in pancreatic cancer: the validation using patient derived pancreatic tumor cell line Kim1, ST; Kim, SY; Lee, J; Kim, K; Park, SH; Park, YS; Lim, HY; Kang, WK; Park, JO
    View PubMed
  • J UROLOGY 2018 10.1016/j.juro.2018.06.030 Changeable Conditional Survival Rates and Associated Prognosticators in Patients with Metastatic Renal Cell Carcinoma Receiving First Line Targeted Therapy Kang1, M; Park, JY; Jeong, CW; Hwang, EC; Song, C; Hong, SH; Kwak, C; Chung, J; Sung, HH; Jeon, HG; Jeong, BC; Park, SH; Jeon, SS; Lee, HM; Choi, HY; Seo, SI
    View PubMed
  • LUNG CANCER 2018 10.1016/j.lungcan.2018.08.003 Continuation of gefitinib beyond progression in patients with EGFR mutation-positive non-small-cell lung cancer: A phase II single-arm trial Lim1, SW; Park, S; Kim, Y; Cho, JH; Park, SE; Lee, H; Kim, HK; Kim, SM; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • CANCER RES TREAT 2018 10.4143/crt.2017.438 Phase II Study of Dovitinib in Patients with Castration-Resistant Prostate Cancer (KCSG-GU11-05) Choi1, YJ; Kim, HS; Park, SH; Kim, BS; Kim, KH; Lee, HJ; Song, HS; Shin, DY; Lee, HY; Kim, HG; Lee, KH; Lee, JL; Park, KH
    View PubMed
  • ANN ONCOL 2018 10.1093/annonc/mdy264 Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300 Bang1, YJ; Ruiz, EY; Van Cutsem, E; Lee, KW; Wyrwicz, L; Schenker, M; Alsina, M; Ryu, MH; Chung, HC; Evesque, L; Al-Batran, SE; Park, SH; Lichinitser, M; Boku, N; Moehler, MH; Hong, J; Xiong, H; Hallwachs, R; Conti, I; Taieb, J
    View PubMed
  • NAT MED 2018 10.1038/s41591-018-0101-z Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer Kim1, ST; Cristescu, R; Bass, AJ; Kim, KM; Odegaard, JI; Kim, K; Liu, XQ; Sher, XW; Jung, H; Lee, M; Lee, S; Park, SH; Park, JO; Park, YS; Lim, HY; Lee, H; Choi, M; Talasaz, A; Kang, PS; Cheng, J; Loboda, A; Lee, J; Kang, WK
    View PubMed
  • J Cancer 2018 10.7150/jca.26068 Antitumor activity of sorafenib plus CDK4/6 inhibitor in pancreatic patient derived cell with KRAS mutation Lee1, T; Kim, K; Lee, J; Park, SH; Park, YS; Lim, HY; Kang, WK; Park, JO; Kim, ST
    View PubMed
  • J THORAC ONCOL 2018 10.1016/j.jtho.2018.05.026 Characteristics and Outcome of ROS1-Positive Non-Small Cell Lung Cancer Patients in Routine Clinical Practice Park1, S; Ahn, BC; Lim, SW; Sun, JM; Kim, HR; Hong, MH; Lee, SH; Ahn, JS; Park, K; La Choi, Y; Cho, BC; Ahn, MJ
    View PubMed
  • CLIN COLORECTAL CANC 2018 10.1016/j.clcc.2018.02.013 c-MET Overexpression in Colorectal Cancer: A Poor Prognostic Factor for Survival Lee1, SJ; Lee, J; Park, SH; Park, JO; Lim, HY; Kang, WK; Park, YS; Kim, ST
    View PubMed
  • BRIT J CANCER 2018 10.1038/s41416-018-0164-0 Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma Powles1, T; Motzer, RJ; Escudier, B; Par, S; Kollmannsberger, C; Pikiel, J; Gurney, H; Rha, SY; Park, SH; Geertsen, PF; Gross-Goupil, M; Grande, E; Suarez, C; Markby, DW; Arroyo, A; Dean, M; Choueiri, TK; George, D
    View PubMed
  • BMC UROL 2018 10.1186/s12894-018-0380-1 Fibroblast growth factor receptor 3 (FGFR3) aberrations in muscle-invasive urothelial carcinoma Kim1, YS; Kim, K; Kwon, GY; Lee, SJ; Park, SH
    View PubMed
  • J Cancer 2018 10.7150/jca.24948 Pemetrexed Monotherapy as Salvage Treatment in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy: A Phase II Single-arm Prospective Trial Lim1, SW; Lee, S; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, ST
    View PubMed
  • INT J UROL 2018 10.1111/iju.13574 Prognostic impact of the pretreatment aspartate transaminase/alanine transaminase ratio in patients treated with first-line systemic tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma Kang1, M; Yu, J; Sung, HH; Jeon, HG; Jeong, BC; Park, SH; Jeon, SS; Lee, HM; Choi, HY; Seo, SI
    View PubMed
  • CLIN COLORECTAL CANC 2018 10.1016/j.clcc.2018.01.005 Phase I Trial of Anti-MET Monoclonal Antibody in MET-Overexpressed Refractory Cancer Lee1, J; Kim, ST; Park, S; Lee, S; Park, SH; Park, JO; Lim, HY; Ahn, H; Bok, H; Kim, KM; Ahn, MJ; Kang, WK; Park, YS
    View PubMed
  • ANN ONCOL 2018 10.1093/annonc/mdy055 Efficacy and safety findings from DREAM: a phase III study of DHP107 (oral paclitaxel) versus i.v. paclitaxel in patients with advanced gastric cancer after failure of first-line chemotherapy Kang1, YK; Ryu, MH; Park, SH; Kim, JG; Kim, JW; Cho, SH; Park, YI; Park, SR; Rha, SY; Kang, MJ; Cho, JY; Kang, SY; Roh, SY; Ryoo, BY; Nam, BH; Jo, YW; Yoon, KE; Oh, SC
    View PubMed
  • ANN ONCOL 2018 10.1093/annonc/mdy034 Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+gastric cancer patients Kim1, ST; Banks, KC; Pectasides, F; Kim, SY; Kim, K; Lanman, RB; Talasaz, A; An, J; Choi, MG; Lee, JH; Sohn, TS; Bae, JM; Kim, S; Park, SH; Park, JO; Park, YS; Lim, HY; Kim, NKD; Park, W; Lee, H; Bass, AJ; Kim, K; Kang, WK; Lee, J
    View PubMed
  • J Cancer 2018 10.7150/jca.25132 The impact of microsatellite instability status and sidedness of the primary tumor on the effect of bevacizumab-containing chemotherapy in patients with metastatic colorectal cancer Kim1, ST; Kim, HK; Lee, J; Park, SH; Lim, HY; Park, YS; Kang, WK; Park, JO
    View PubMed
  • TRANSL ONCOL 2018 10.1016/j.tranon.2018.01.007 The Correlation Between Serum Chemokines and Clinical Outcome in Patients with Advanced Biliary Tract Cancer Lee1, SJ; Kim, JE; Kim, ST; Lee, J; Park, SH; Park, JO; Kang, WK; Park, YS; Lim, HY
    View PubMed
  • CANCER RES TREAT 2018 10.4143/crt.2016.584 Pazopanib for the Treatment of Non-clear Cell Renal Cell Carcinoma: A Single-Arm, Open-Label, Multicenter, Phase II Study Jung1, KS; Lee, SJ; Park, SH; Lee, JL; Lee, SH; Lim, JY; Kang, JH; Lee, S; Rha, SY; Lee, KH; Kim, HY; Lim, HY
    View PubMed
  • TRANSL ONCOL 2018 10.1016/j.tranon.2017.10.008 Molecular Characterization of Urothelial Carcinoma of the Bladder and Upper Urinary Tract Lee1, JY; Kim, K; Sung, HH; Jeon, HG; Jeong, BC; Seo, SI; Jeon, SS; Lee, HM; Choi, HY; Kwon, GY; Kim, KM; Lee, J; Lim, HY; Park, SH
    View PubMed
  • J GYNECOL ONCOL 2018 10.3802/jgo.2018.29.e3 Pazopanib monotherapy in the treatment of pretreated, metastatic uterine sarcoma: a single-center retrospective study Kim1, HJ; Kim, Y; Lee, SJ; Lee, J; Park, SH
    View PubMed
  • ONCOTARGET 2017 10.18632/oncotarget.18182 Correlation between MEK signature and Ras gene alteration in advanced gastric cancer Ahn1, S; Brant, R; Sharpe, A; Dry, JR; Hodgson, DR; Kilgour, E; Kim, K; Kim, ST; Park, SH; Kang, WK; Kim, KM; Lee, J
    View PubMed
  • CANCER CHEMOTH PHARM 2017 10.1007/s00280-017-3445-z A non-randomized, open-label, single-arm, Phase 2 study of emibetuzumab in Asian patients with MET diagnostic positive, advanced gastric cancer Sakai1, D; Chung, HC; Oh, DY; Park, SH; Kadowaki, S; Kim, YH; Tsuji, A; Komatsu, Y; Kang, YK; Uenaka, K; Wijayawardana, SR; Wacheck, V; Wang, XJ; Yamamura, A; Doi, T
    View PubMed
  • ONCOTARGET 2017 10.18632/oncotarget.22394 MerTK inhibition by RXDX-106 in MerTK activated gastric cancer cell lines Kim1, JE; Kim, Y; Li, G; Kim, ST; Kim, K; Park, SH; Park, JO; Park, YS; Lim, HY; Lee, H; Sohn, TS; Kim, KM; Kang, WK; Lee, J
    View PubMed
  • LANCET ONCOL 2017 10.1016/S1470-2045(17)30682-4 Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial Bang1, YJ; Xu, RH; Chin, K; Lee, KW; Park, SH; Rha, SY; Shen, L; Qin, S; Xu, N; Im, SA; Locker, G; Rowe, P; Shi, XJ; Hodgson, D; Liu, YZ; Boku, N
    View PubMed
  • INVEST NEW DRUG 2017 10.1007/s10637-017-0463-y Phase I trial and pharmacokinetic study of tanibirumab, a fully human monoclonal antibody to vascular endothelial growth factor receptor 2, in patients with refractory solid tumors Lee1, SJ; Lee, SY; Lee, WS; Yoo, JS; Sun, JM; Lee, J; Park, SH; Park, JO; Ahn, MJ; Lim, HY; Kang, WK; Park, YS
    View PubMed
  • ONCOTARGET 2017 10.18632/oncotarget.3750 MerTK is a novel therapeutic target in gastric cancer Yi1, JH; Jang, J; Cho, J; Do, IG; Hong, M; Kim, ST; Kim, KM; Lee, S; Park, SH; Park, JO; Park, YS; Kang, WK; Lim, HY; Lee, J
    View PubMed
  • Oncoimmunology 2017 10.1080/2162402X.2017.1356150 Host immune response index in gastric cancer identified by comprehensive analyses of tumor immunity Park1, C; Cho, J; Lee, J; Kang, SY; An, JY; Choi, MG; Lee, JH; Sohn, TS; Bae, JM; Kim, S; Kim, ST; Park, SH; Park, JO; Kang, WK; Sohn, I; Jung, SH; Kang, MS; Kim, KM
    View PubMed
  • ONCOLOGIST 2017 10.1634/theoncologist.2017-0020 Clinical Application of Targeted Deep Sequencing in Solid-Cancer Patients and Utility for Biomarker-Selected Clinical Trials Kim1, ST; Kim, KM; Kim, NKD; Park, JO; Ahn, S; Yun, JW; Kim, KT; Park, SH; Park, PJ; Kim, HC; Sohn, TS; Il Choi, D; Cho, JH; Heo, JS; Kwon, W; Lee, H; Min, BH; Hong, SN; Park, YS; Lim, HY; Kang, WK; Park, WY; Lee, J
    View PubMed
  • ONCOTARGET 2017 10.18632/oncotarget.19985 Development of mesenchymal subtype gene signature for clinical application in gastric cancer Lee1, J; Cristescu, R; Kim, KM; Kim, K; Kim, ST; Park, SH; Kang, WK
    View PubMed
  • ONCOTARGET 2017 10.18632/oncotarget.20492 Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types: implications for immunotherapy Kim1, ST; Klempner, SJ; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, KM; Lee, J
    View PubMed
  • ONCOTARGET 2017 10.18632/oncotarget.18168 The impact of pathologic differentiation (well/poorly) and the degree of Ki-67 index in patients with metastatic WHO grade 3 GEP-NECs Kim1, HK; Ha, SY; Lee, J; Park, SH; Park, JO; Lim, HY; Kang, WK; Park, YS; Kim, ST
    View PubMed
  • TRANSL ONCOL 2017 10.1016/j.tranon.2017.03.001 Antitumor Effect of AZD4547 in a Fibroblast Growth Factor Receptor 2-Amplified Gastric Cancer Patient-Derived Cell Model Jang1, J; Kim, HK; Bang, H; Kim, ST; Kim, SY; Park, SH; Lim, HY; Kang, WK; Lee, J; Kim, KM
    View PubMed
  • BMC UROL 2017 10.1186/s12894-017-0253-z A retrospective feasibility study of biweekly, reduced-dose docetaxel in Asian patients with castrate-resistant, metastatic prostate cancer Kim1, HS; Lee, JY; Lee, SJ; Lim, HY; Sung, HH; Jeon, HG; Jeong, BC; Seo, SI; Jeon, SS; Lee, HM; Choi, HY; Park, SH
    View PubMed
  • J Cancer 2017 10.7150/jca.18286 The Impact of Microsatellite Instability Status and Sidedness of the Primary Tumor on the Effect of Cetuximab-Containing Chemotherapy in Patients with Metastatic Colorectal Cancer Kim1, ST; Lee, SJ; Lee, J; Park, SH; Park, JO; Lim, HY; Kang, WK; Park, YS
    View PubMed
  • CANCER RES TREAT 2017 10.4143/crt.2016.417 A Randomized Phase II Study of Leucovorin/5-Fluorouracil with or without Oxaliplatin (LV5FU2 vs. FOLFOX) for Curatively-Resected, Node-Positive Esophageal Squamous Cell Carcinoma Lim1, SH; Shim, YM; Park, SH; Kim, HK; Choi, YS; Ahn, MJ; Park, K; Zo, JI; Sun, JM
    View PubMed
  • J Cancer 2017 10.7150/jca.19582 MAP2K1 Mutation in Colorectal Cancer Patients: Therapeutic Challenge Using Patient-Derived Tumor Cell Lines Kim1, JE; Kim, KK; Kim, SY; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, ST
    View PubMed
  • Ann Oncol. 2017 Mar 1;28(3):547-554. doi: 10.1093/annonc/mdw669. Rapamycin-insensitive companion of mTOR (RICTOR) amplification defines a subset of advanced gastric cancer and is sensitive to AZD2014-mediated mTORC1/2 inhibition Kim ST11, Kim SY1, Klempner SJ2,3, Yoon J4, Kim N4, Ahn S4,5, Bang H5,6, Kim KM5,6, Park W4, Park SH1, Park JO1, Park YS1, Lim HY1, Lee SH1, Park K1,6, Kang WK1, Lee J1.
    View PubMed
  • BMC Cancer. 2017 Mar 23;17(1):211. doi: 10.1186/s12885-017-3196-6. Prospective phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy Kim ST11, Lee J1, Park SH1, Park JO1, Park YS1, Kang WK1, Lim HY2.
    View PubMed
  • Oncotarget. 2017 Feb 28;8(9):15014-15022. doi: 10.18632/oncotarget.14788. Acquired resistance to LY2874455 in FGFR2-amplified gastric cancer through an emergence of novel FGFR2-ACSL5 fusion Kim SY11, Ahn T2, Bang H3, Ham JS1, Kim J1, Kim ST1, Jang J1, Shim M1, Kang SY3, Park SH1, Min BH4, Lee H4, Kang WK1, Kim KM3, Park W2,5, Lee J1.
    View PubMed
  • Oncotarget. 2017 Feb 21;8(8):13320-13328. doi: 10.18632/oncotarget.14519. Programmed cell death-ligand 1 expression predicts survival in patients with gastric carcinoma with microsatellite instability Cho J11, Lee J2, Bang H3, Kim ST2, Park SH2, An JY4, Choi MG4, Lee JH4, Sohn TS4, Bae JM4, Kang WK2, Kim S4, Kim KM3.
    View PubMed
  • Asia Pac J Clin Oncol. 2017 Feb;13(1):61-67. doi: 10.1111/ajco.12465. Epub 2016 Mar 31. Intrinsic resistance to sunitinib in patients with metastatic renal cell carcinoma Lim SH11, Hwang IG2, Ji JH3, Oh SY4, Yi JH5, Lim DH6, Lim HY1, Lee SJ1, Park SH1.
    View PubMed
  • Oncotarget. 2017 Feb 14;8(7):11094-11104. doi: 10.18632/oncotarget.14362. Direct analysis of aberrant glycosylation on haptoglobin in patients with gastric cancer Kim JH11, Lee SH2, Choi S2, Kim U3, Yeo IS4, Kim SH2, Oh MJ3, Moon H3, Lee J3, Jeong S3, Choi MG5, Lee JH5, Sohn TS5, Bae JM5, Kim S5, Min YW5, Lee H5, Lee JH5, Rhee PL5, Kim JJ5, Lee SJ5, Kim ST5, Lee J5, Park SH5, Park JO5, Park YS5, Lim HY5, Kang WK5, An HJ3, Kim JH4.
    View PubMed
  • Oncotarget. 2017 Jan 10;8(2):3237-3245. doi: 10.18632/oncotarget.13700. The implication of FLT3 amplification for FLT targeted therapeutics in solid tumors Lim SH11, Kim SY1, Kim K2, Jang H1, Ahn S2, Kim KM2, Kim NK3, Park W3, Lee SJ1, Kim ST1, Park SH1, Park JO1, Park YS1, Lee SH1, Lim HY1, Park K1, Kang WK1, Lee J1.
    View PubMed
  • Mol Biosyst. 2016 Nov 15;12(12):3611-3621. Glycomic profiling of targeted serum haptoglobin for gastric cancer using nano LC/MS and LC/MS/MS Lee SH11, Jeong S2, Lee J2, Yeo IS3, Oh MJ2, Kim U2, Kim S2, Kim SH1, Park SY4, Kim JH5, Park SH6, Kim JH3, An HJ2.
    View PubMed
  • J Cancer. 2016 Oct 25;7(15):2173-2178. eCollection 2016. To Excavate Biomarkers Predictive of the Response for Capecitabine plus RAD001 through Nanostring-Based Multigene Assay in Advanced Gastric Cancer Patients Lee H11, Lee J2, Sohn I3, Park SH2, Park JO2, Park YS2, Kim KM4, Kang WK2, Kim ST2.
    View PubMed
  • CANCER RESEARCH AND TREATMENT, OCT 2016, 48(4) :1274-1285, DOI: 10.4143/crt.2015.502 Is There a Role for Adjuvant Therapy in RO Resected Gallbladder Cancer?: A Propensity Score-Matched Analysis Go SI1, Kim YS, Hwang IG, Kim EY, Oh SY, Ji JH, Song HN, Park SH, Park JO, Kang JH
    View PubMed
  • Biochem J. 2016 Sep 1;473(17):2603-10. doi: 10.1042/BCJ20160482. Epub 2016 Jun 22. Critical role of XBP1 in cancer signalling is regulated by PIN1 Chae U11, Park SJ2, Kim B1, Wei S3, Min JS4, Lee JH5, Park SH6, Lee AH7, Lu KP3, Lee DS8, Min SH9.
    View PubMed
  • Mod Pathol. 2016 Sep;29(9):1095-103. doi: 10.1038/modpathol.2016.96. Epub 2016 May 27. FGFR2 in gastric cancer: protein overexpression predicts gene amplification and high H-index predicts poor survival Ahn S11,2, Lee J3, Hong M4, Kim ST3, Park SH3, Choi MG5, Lee JH5, Sohn TS5, Bae JM5, Kim S5, Jung SH6, Kang WK3, Kim KM1,2.
    View PubMed
  • BMC Urol. 2016 Aug 2;16(1):46. doi: 10.1186/s12894-016-0163-5. A Korean multi-center, real-world, retrospective study of first-line pazopanib in unselected patients with metastatic renal clear-cell carcinoma Kim MJ11, Park SH2, Lee JL3, Lee SH4, Lee SJ5, Lim HY5.
    View PubMed
  • Mol Diagn Ther. 2016 Aug;20(4):375-83. doi: 10.1007/s40291-016-0205-4. A nCounter CNV Assay to Detect HER2 Amplification: A Correlation Study with Immunohistochemistry and In Situ Hybridization in Advanced Gastric Cancer Ahn S11,2, Hong M3, Van Vrancken M4, Lyou YJ2, Kim ST5, Park SH5, Kang WK5, Park YS5, Jung SH6, Woo M6, Lee J7, Kim KM8,9.
    View PubMed
  • J Cancer. 2016 Jul 27;7(12):1711-1715. eCollection 2016. Factors Influencing Clinicians' Choice of Adjuvant S-1 versus Capecitabine plus Oxaliplatin after Curative Gastrectomy in Patients with Gastric Cancer Lee HY11, Hwang IG2, Park SE2, Kim MJ3, Park SH4, Kang JH5, Kim YS6, Oh SY7, Won YW8, Lee SI9, Ji JH10, Chi KC11.
    View PubMed
  • Oncotarget. 2016 Jul 12;7(28):43492-43503. doi: 10.18632/oncotarget.9523. MCT4 as a potential therapeutic target for metastatic gastric cancer with peritoneal carcinomatosis Lee JY11, Lee I2, Chang WJ3, Ahn SM4,5, Lim SH1, Kim HS1, Yoo KH1, Jung KS1, Song HN1, Cho JH1, Kim SY1, Kim KM4,5, Lee S1, Kim ST1, Park SH1, Lee J1, Park JO1, Park YS1, Lim HY1, Kang WK1.
    View PubMed
  • Transl Oncol. 2016 Jun;9(3):197-202. doi: 10.1016/j.tranon.2016.03.008. Epub 2016 May 12. BEZ235 (PIK3/mTOR inhibitor) Overcomes Pazopanib Resistance in Patient-Derived Refractory Soft Tissue Sarcoma Cells Kim HK11, Kim SY1, Lee SJ1, Kang M1, Kim ST1, Jang J1, Rath O2, Schueler J2, Lee DW3, Park WY4, Kim SJ5, Park SH1, Lee J6.
    View PubMed
  • Bone Marrow Transplant. 2016 Jun;51(6):807-12. doi: 10.1038/bmt.2016.6. Epub 2016 Feb 8. Prognostic relevance of pretransplant Deauville score on PET-CT and presence of EBV DNA in patients who underwent autologous stem cell transplantation for ENKTL Lim SH11, Hyun SH2, Kim HS1, Lee JY1, Yoo KH1, Jung KS1, Song HN1, Cho J1, Park S1, Ko YH3, Kim SJ1, Choi JY2, Kim WS1.
    View PubMed
  • J Cancer Res Clin Oncol. 2016 Jun;142(6):1231-7. doi: 10.1007/s00432-016-2143-2. Epub 2016 Mar 16. Value of FGFR2 expression for advanced gastric cancer patients receiving pazopanib plus CapeOX (capecitabine and oxaliplatin) Kim ST11, Ahn S2, Lee J1, Lee SJ1, Park SH1, Park YS1, Lim HY1, Kang WK1, Kim KM2, Park JO3.
    View PubMed
  • Cancer Chemother Pharmacol. 2016 May;77(5):979-85. doi: 10.1007/s00280-016-3014-x. Epub 2016 Mar 26. Role of adjuvant therapy after R0 resection for patients with distal cholangiocarcinoma Kim YS11, Hwang IG2, Park SE3, Go SI4, Kang JH4, Park I1, Oh SY5, Ji JH6, Song HN7, Park SH7, Kim ST7, Park JO7.
    View PubMed
  • J Cancer. 2016 May 25;7(9):1044-8. doi: 10.7150/jca.14815. eCollection 2016. Genomic Profiling of Metastatic Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients in the Personalized-Medicine Era Kim ST11, Lee SJ1, Park SH1, Park JO1, Lim HY1, Kang WK1, Lee J1, Park YS1.
    View PubMed
  • JOURNAL OF CLINICAL ONCOLOGY, APR 20 2016, 34(12):1422, DOI: 10.1200/JCO.2015.65.6975 Chemoradiotherapy in Gastric Cancer: A Door Ajar Reply Park SH1, Kang WK
    View PubMed
  • Cancer Res Treat. 2016 Apr;48(2):553-60. doi: 10.4143/crt.2015.155. Epub 2015 Aug 10. A Retrospective Analysis for Patients with HER2-Positive Gastric Cancer Who Were Treated with Trastuzumab-Based Chemotherapy: In the Perspectives of Ethnicity and Histology Yi JH11, Kang JH2, Hwang IG3, Ahn HK4, Baek HJ5, Lee SI5, Lim DH5, Won YW6, Ji JH7, Kim HS8, Rha SY8, Oh SY9, Lee KE10, Lim T11, Maeng CH12, Kim MJ13, Kim ST13, Lee J13, Park JO13, Park YS13, Lim HY13, Kang WK13, Park SH13.
    View PubMed
  • Oncotarget. 2016 Apr 26;7(17):24088-96. doi: 10.18632/oncotarget.8175. Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer Kim ST11, Lee J1, Lee SJ1, Park SH1, Jung SH2, Park YS1, Lim HY1, Kang WK1, Park JO1.
    View PubMed
  • Br J Cancer. 2016 Feb 16;114(4):381-7. doi: 10.1038/bjc.2015.452. Chemotherapy vs supportive care alone for relapsed gastric, gastroesophageal junction, and oesophageal adenocarcinoma: a meta-analysis of patient-level data Janowitz T11, Thuss-Patience P2, Marshall A3, Kang JH4, Connell C1, Cook N1, Dunn J2,3, Park SH5, Ford H1.
    View PubMed
  • Clin Genitourin Cancer. 2016 Feb;14(1):76-81. doi: 10.1016/j.clgc.2015.09.008. Epub 2015 Sep 25. A Phase II Study of Weekly Docetaxel as Second-Line Chemotherapy in Patients With Metastatic Urothelial Carcinoma Kim YS11, Lee SI2, Park SH3, Park S3, Hwang IG4, Lee SC5, Sun JM3, Lee J3, Lim HY3.
    View PubMed
  • J Cancer. 2016 Feb 5;7(5):484-9. doi: 10.7150/jca.13711. eCollection 2016. The Impact of PD-L1 Expression in Patients with Metastatic GEP-NETs Kim ST11, Ha SY2, Lee S1, Ahn S2, Lee J1, Park SH1, Park JO1, Lim HY1, Kang WK1, Kim KM2, Park YS1.
    View PubMed
  • Cancer Res Treat. 2016 Jan;48(1):20-7. doi: 10.4143/crt.2014.317. Epub 2015 Mar 2. Current Status and Challenges of Cancer Clinical Trials in Korea Shim BY11, Park SH2, Lee S3, Kim JS4, Lee KE5, Kang YK6, Ahn MJ2.
    View PubMed
  • Cancer Res Treat. 2016 Jan;48(1):153-61. doi: 10.4143/crt.2014.183. Epub 2015 Mar 7. The Role of Plasma Chromogranin A as Assessment of Treatment Response in Non-functioning Gastroenteropancreatic Neuroendocrine Tumors Kim M11, Lee S2, Lee J2, Park SH2, Park JO2, Park YS2, Kang WK2, Kim ST2.
    View PubMed
  • Oncotarget. 2015 Nov 24;6(37):40360-9. doi: 10.18632/oncotarget.5465. Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients Kim ST11, Lee WS2, Lanman RB3, Mortimer S3, Zill OA3, Kim KM4,5, Jang KT5, Kim SH5, Park SH1, Park JO1,4, Park YS1, Lim HY1, Eltoukhy H3, Kang WK1, Lee WY6, Kim HC6, Park K1,4, Lee J1,4, Talasaz A3.
    View PubMed
  • Br J Cancer. 2015 Nov 17;113(10):1421-6. doi: 10.1038/bjc.2015.371. Epub 2015 Oct 27. A randomised, double-blind, placebo-controlled multi-centre phase III trial of XELIRI/FOLFIRI plus simvastatin for patients with metastatic colorectal cancer Lim SH11, Kim TW2, Hong YS2, Han SW3, Lee KH3, Kang HJ4, Hwang IG5, Lee JY1, Kim HS1, Kim ST1, Lee J1, Park JO1, Park SH1, Park YS1, Lim HY1, Jung SH6,7, Kang WK1.
    View PubMed
  • Oncotarget. 2015 Oct 20;6(32):33358-68. doi: 10.18632/oncotarget.5188. The NEXT-1 (Next generation pErsonalized tX with mulTi-omics and preclinical model) trial: prospective molecular screening trial of metastatic solid cancer patients, a feasibility analysis Kim ST11, Lee J1, Hong M2,3, Park K4,5, Park JO1, Ahn T3,4, Park SH1, Park YS1, Lim HY1, Sun JM1, Ahn JS1, Ahn MJ1, Kim HC6, Sohn TS6, Choi DI7, Cho JH8, Heo JS6, Kwon W6, Uhm SW9, Lee H10, Min BH10, Hong SN10, Kim DH5,11, Jung SH12, Park W4,5, Kim KM2,3, Kang WK1, Park K1,2.
    View PubMed
  • Radiother Oncol. 2015 Oct;117(1):171-7. doi: 10.1016/j.radonc.2015.08.009. Epub 2015 Aug 20. Effects of adjuvant radiotherapy on completely resected gastric cancer: A radiation oncologist's view of the ARTIST randomized phase III trial Yu JI11, Lim do H2, Ahn YC1, Lee J3, Kang WK3, Park SH3, Park JO3, Park YS3, Lim HY3, Kim ST3, Kim S4, Sohn TS4, Choi MG4, Bae JM4, Nam H5.
    View PubMed
  • Int J Biol Markers. 2015 Nov 11;30(4):e382-6. doi: 10.5301/jbm.5000151. Circulating tumor cells are predictive of poor response to chemotherapy in metastatic gastric cancer Lee SJ11, Lee J1, Kim ST1, Park SH1, Park JO1, Park YS1, Lim HY1, Kang WK1.
    View PubMed
  • BMC Cancer. 2015 Oct 14;15:693. doi: 10.1186/s12885-015-1716-9. Capecitabine in combination with either cisplatin or weekly paclitaxel as a first-line treatment for metastatic esophageal squamous cell carcinoma: a randomized phase II study Lee SJ11, Kim S2, Kim M3, Lee J4, Park YH5, Im YH6, Park SH7.
    View PubMed
  • BMC Cancer. 2015 Oct 20;15:747. doi: 10.1186/s12885-015-1759-y. Exploratory biomarker analysis for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecan Kim ST1, Ahn TJ, Lee E, Do IG, Lee SJ, Park SH, Park JO, Park YS, Lim HY, Kang WK, Kim SH, Lee J, Kim HC
    View PubMed
  • Gastric Cancer. 2015 Oct;18(4):824-32. doi: 10.1007/s10120-014-0420-9. Epub 2014 Sep 5. Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer Satoh T11, Lee KH2, Rha SY3, Sasaki Y4, Park SH5, Komatsu Y6, Yasui H7, Kim TY8, Yamaguchi K9, Fuse N10, Yamada Y11, Ura T12, Kim SY13, Munakata M14, Saitoh S15, Nishio K16, Morita S17, Yamamoto E18, Zhang Q19, Kim JM20, Kim YH21, Sakata Y14.
    View PubMed
  • J Clin Oncol. 2015 Oct 1;33(28):3130-6. doi: 10.1200/JCO.2014.58.3930. Epub 2015 Jan 5. Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses Park SH11, Sohn TS1, Lee J1, Lim DH1, Hong ME1, Kim KM1, Sohn I1, Jung SH1, Choi MG1, Lee JH1, Bae JM1, Kim S1, Kim ST1, Park JO1, Park YS1, Lim HY1, Kang WK2.
    View PubMed
  • BMC Palliat Care. 2015 Sep 16;14:41. doi: 10.1186/s12904-015-0038-7. Opioid rotation versus combination for cancer patients with chronic uncontrolled pain: a randomized study Kim HJ11, Kim YS2, Park SH3.
    View PubMed
  • Oncotarget. 2015 Sep 22;6(28):25619-30. doi: 10.18632/oncotarget.4627. Patient-derived cell models as preclinical tools for genome-directed targeted therapy Lee JY11, Kim SY1, Park C1, Kim NK2, Jang J1, Park K2, Yi JH3, Hong M4,5, Ahn T2, Rath O6, Schueler J6, Kim ST1, Do IG5, Lee S1, Park SH1, Ji YI7, Kim D7, Park JO1,4, Park YS1, Kang WK1, Kim KM4,5, Park WY2,7, Lim HY1, Lee J1,4.
    View PubMed
  • Mol Ther. 2015 Sep;23(9):1532-40. doi: 10.1038/mt.2015.109. Epub 2015 Jun 15. Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer Park SH11, Breitbach CJ2, Lee J1, Park JO1, Lim HY1, Kang WK1, Moon A2,3, Mun JH4, Sommermann EM4, Maruri Avidal L4, Patt R5, Pelusio A2, Burke J2, Hwang TH4,6, Kirn D2, Park YS1.
    View PubMed
  • Oncotarget. 2015 Sep 29;6(29):28211-22. doi: 10.18632/oncotarget.4721. Gastrointestinal malignancies harbor actionable MET exon 14 deletions Lee J11,2, Ou SH3, Lee JM4, Kim HC5, Hong M6, Kim SY1, Jang J1, Ahn S6, Kang SY6, Lee S1, Kim ST1, Kim B4, Choi J4, Kim KA4, Lee J1, Park C1,6, Park SH1, Park JO1,2, Lim HY1, Kang WK1, Park K1,2, Park YS1, Kim KM2,6.
    View PubMed
  • World J Gastroenterol. 2015 Aug 7;21(29):8811-6. doi: 10.3748/wjg.v21.i29.8811. Chemotherapy beyond second-line in advanced gastric cancer Kim SM11, Park SH1.
    View PubMed
  • Transl Oncol. 2015 Aug;8(4):288-94. doi: 10.1016/j.tranon.2015.06.001. Clinical Significance of IGFBP-3 Methylation in Patients with Early Stage Gastric Cancer Kim ST11, Jang HL2, Lee J1, Park SH1, Park YS1, Lim HY1, Choi MG3, Bae JM3, Sohn TS3, Noh JH3, Kim S3, Kim KM4, Kang WK1, Park JO5.
    View PubMed
  • BMC Cancer. 2015 Jul 21;15:530. doi: 10.1186/s12885-015-1552-y. Tumour shrinkage at 6 weeks predicts favorable clinical outcomes in a phase III study of gemcitabine and oxaliplatin with or without erlotinib for advanced biliary tract cancer Kim ST11, Jang KT2, Lee SJ3, Jang HL4, Lee J5, Park SH6, Park YS7, Lim HY8, Kang WK9, Park JO10.
    View PubMed
  • Nat Med. 2015 May;21(5):449-56. doi: 10.1038/nm.3850. Epub 2015 Apr 20. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes Cristescu R11, Lee J2, Nebozhyn M1, Kim KM3, Ting JC4, Wong SS4, Liu J4, Yue YG4, Wang J4, Yu K4, Ye XS4, Do IG3, Liu S5, Gong L5, Fu J6, Jin JG6, Choi MG7, Sohn TS7, Lee JH7, Bae JM7, Kim ST2, Park SH2, Sohn I8, Jung SH8, Tan P9, Chen R1, Hardwick J1, Kang WK2, Ayers M1, Hongyue D1, Reinhard C4, Loboda A1, Kim S7, Aggarwal A4.
    View PubMed
  • Int J Cancer. 2015 Apr 1;136(7):1629-35. doi: 10.1002/ijc.29159. Epub 2014 Sep 4. HER2-positive gastric cancer with concomitant MET and/or EGFR overexpression: A distinct subset of patients for dual inhibition therapy Ha SY11, Lee J, Jang J, Hong JY, Do IG, Park SH, Park JO, Choi MG, Sohn TS, Bae JM, Kim S, Kim M, Kim S, Park CK, Kang WK, Kim KM.
    View PubMed
  • World J Gastroenterol. 2015 Apr 14;21(14):4268-74. doi: 10.3748/wjg.v21.i14.4268. Weekly docetaxel and gemcitabine in previously treated metastatic esophageal squamous cell carcinoma Lee MY11, Jung KS1, Kim HS1, Lee JY1, Lim SH1, Kim M1, Jung HA1, Kim SM1, Sun JM1, Ahn MJ1, Lee J1, Park SH1, Yi SY1, Hwang IG1, Lee SC1, Ahn HK1, Lim do H1, Lee SI1, Park KW1.
    View PubMed
  • World J Gastroenterol. 2015 Apr 14;21(14):4268-74. doi: 10.3748/wjg.v21.i14.4268. Weekly docetaxel and gemcitabine in previously treated metastatic esophageal squamous cell carcinoma Lee MY11, Jung KS1, Kim HS1, Lee JY1, Lim SH1, Kim M1, Jung HA1, Kim SM1, Sun JM1, Ahn MJ1, Lee J1, Park SH1, Yi SY1, Hwang IG1, Lee SC1, Ahn HK1, Lim DH1, Lee SI1, Park KW1.
    View PubMed
  • Jpn J Clin Oncol. 2015 Mar;45(3):256-60. doi: 10.1093/jjco/hyu210. Epub 2015 Jan 26. Natural history of metastatic biliary tract cancer (BTC) patients with good performance status (PS) who were treated with only best supportive care (BSC) Ji JH11, Song HN2, Kim RB3, Oh SY4, Lim HY5, Park JO5, Park SH5, Kim MJ5, Lee SI6, Ryou SH6, Hwang IG7, Jang JS7, Kim HJ8, Choi JY9, Kang JH10.
    View PubMed
  • Sci Rep. 2015 Mar 19;5:9289. doi: 10.1038/srep09289. The Impact of Concomitant Genomic Alterations on Treatment Outcome for Trastuzumab Therapy in HER2-Positive Gastric Cancer Lee JY11, Hong M2, Kim ST1, Park SH1, Kang WK1, Kim KM2, Lee J1.
    View PubMed
  • BMC Cancer. 2015 Mar 19;15:154. doi: 10.1186/s12885-015-1160-x. Efficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic soft tissue sarcoma: a retrospective case series Yoo KH11, Kim HS2, Lee SJ3, Park SH4, Kim SJ5, Kim SH6, La Choi Y7, Shin KH8, Cho YJ9, Lee J10, Rha SY11.
    View PubMed
  • World J Gastroenterol. 2015 Feb 14;21(6):1845-50. doi: 10.3748/wjg.v21.i6.1845. Retrospective analysis of extra-gastrointestinal stromal tumors Yi JH11, Park BB1, Kang JH1, Hwang IG1, Shin DB1, Sym SJ1, Ahn HK1, Lee SI1, Lim do H1, Park KW1, Won YW1, Lim SH1, Park SH1.
    View PubMed
  • Transl Oncol. 2015 Feb;8(1):40-6. doi: 10.1016/j.tranon.2014.12.003. Molecular Subgroup Analysis of Clinical Outcomes in a Phase 3 Study of Gemcitabine and Oxaliplatin with or without Erlotinib in Advanced Biliary Tract Cancer Kim ST11, Jang KT2, Lee J1, Jang HM3, Choi HJ4, Jang HL1, Park SH1, Park YS1, Lim HY1, Kang WK1, Park JO5.
    View PubMed
  • Korean J Intern Med. 2015 Jan;30(1):88-95. doi: 10.3904/kjim.2015.30.1.88. Epub 2014 Dec 30. The efficacy of low-dose transdermal fentanyl in opioid-naive cancer patients with moderate-to-severe pain Kang JH11, Oh SY2, Song SY3, Lee HY3, Kim JH4, Lee KE5, Lee HR6, Hwang IG7, Park SH8, Kim WS8, Park YS8, Park K8.
    View PubMed
  • Cancer Res Treat. 2015 Jan;47(1):72-7. doi: 10.4143/crt.2013.172. Epub 2014 Aug 21. Changes in the Mean Corpuscular Volume after Capecitabine Treatment are Associated with Clinical Response and Survival in Patients with Advanced Gastric Cancer Jung HA11, Kim HJ2, Maeng CH3, Park SH1, Lee J1, Park JO1, Park YS1, Lim HY1, Kang WK1.
    View PubMed
  • Sci Rep. 2014 Dec 23;4:7592. doi: 10.1038/srep07592. Anti-tumor efficacy of fulvestrant in estrogen receptor positive gastric cancer Yi JH11, Do IG2, Jang J3, Kim ST3, Kim KM4, Park SH3, Park JO3, Park YS3, Lim HY3, Kang WK3, Lee J3.
    View PubMed
  • Mol Cancer Ther. 2014 Nov;13(11):2527-36. doi: 10.1158/1535-7163.MCT-14-0255. Epub 2014 Sep 23. Pazopanib, a Novel Multitargeted Kinase Inhibitor, Shows Potent In Vitro Antitumor Activity in Gastric Cancer Cell Lines with FGFR2 Amplification Kim ST11, Jang HL2, Lee SJ1, Lee J1, Choi YL3, Kim KM3, Cho J4, Park SH1, Park YS1, Lim HY1, Yashiro M5, Kang WK1, Park JO6.
    View PubMed
  • Eur J Cancer. 2014 Nov;50(16):2822-30. doi: 10.1016/j.ejca.2014.08.005. Epub 2014 Sep 15. Simvastatin plus capecitabine-cisplatin versus placebo plus capecitabine-cisplatin in patients with previously untreated advanced gastric cancer: A double-blind randomised phase 3 study Kim ST11, Kang JH2, Lee J1, Park SH1, Park JO1, Park YS1, Lim HY1, Hwang IG3, Lee SC4, Park KW5, Lee HR6, Kang WK7.
    View PubMed
  • Cancer Chemother Pharmacol. 2014 Nov;74(5):1005-13. doi: 10.1007/s00280-014-2579-5. Epub 2014 Sep 6. Effectiveness and safety of cabazitaxel plus prednisolone chemotherapy for metastatic castration-resistant prostatic carcinoma: data on Korean patients obtained by the cabazitaxel compassionate-use program Lee JL11, Park SH, Koh SJ, Lee SH, Kim YJ, Choi YJ, Lee J, Lim HY.
    View PubMed
  • PLoS One. 2014 Nov 5;9(11):e111693. doi: 10.1371/journal.pone.0111693. eCollection 2014. High-Throughput Sequencing and Copy Number Variation Detection Using Formalin Fixed Embedded Tissue in Metastatic Gastric Cancer Kim S11, Lee J2, Hong ME3, Do IG3, Kang SY1, Ha SY1, Kim ST2, Park SH2, Kang WK2, Choi MG4, Lee JH4, Sohn TS4, Bae JM4, Kim S4, Kim DH5, Kim KM3.
    View PubMed
  • Anticancer Res. 2014 Nov;34(11):6585-91. Adjuvant Chemoradiation with 5-Fluorouracil/Leucovorin versus S-1 in Gastric Cancer Patients Following D2 Lymph Node Dissection Surgery: A Feasibility Study Lee SJ11, Sohn TS2, Lee J1, Park SH1, Park JO1, Lim DH3, Park YS1, Lim HY1, Choi MG4, Lee JH4, Bae JM4, Kim S4, Kang WK5.
    View PubMed
  • Invest New Drugs. 2014 Jun;32(3):535-41. doi: 10.1007/s10637-014-0065-x. Epub 2014 Jan 28. Effect of simvastatin plus cetuximab/irinotecan for KRAS mutant colorectal cancer and predictive value of the RAS signature for treatment response to cetuximab Lee J11, Hong YS, Hong JY, Han SW, Kim TW, Kang HJ, Kim TY, Kim KP, Kim SH, Do IG, Kim KM, Sohn I, Park SH, Park JO, Lim HY, Cho YB, Lee WY, Yun SH, Kim HC, Park YS, Kang WK.
    View PubMed
  • Ann Surg Oncol. 2014 Apr;21(4):1099-106. doi: 10.1245/s10434-013-3339-1. Epub 2013 Dec 4. CD151 Overexpression is Associated with Poor Prognosis in Patients with pT3 Gastric Cancer Ha SY11, Do IG, Lee J, Park SH, Park JO, Kang WK, Choi MG, Lee JH, Bae JM, Kim S, Kim KM, Sohn TS.
    View PubMed
  • Chemotherapy. 2014;60(2):73-80. doi: 10.1159/000368071. Epub 2014 Nov 29. Treatment Outcome and Relevance of Palliative Chemotherapy in Urachal Cancer Jung HA11, Sun JM, Park SH, Kwon GY, Lim HY.
    View PubMed
  • PLoS One. 2014 Mar 5;9(3):e90133. doi: 10.1371/journal.pone.0090133. eCollection 2014. Nanostring-Based Multigene Assay to Predict Recurrence for Gastric Cancer Patients after Surgery Lee J11, Sohn I2, Do IG3, Kim KM4, Park SH1, Park JO1, Park YS1, Lim HY1, Sohn TS5, Bae JM5, Choi MG5, Lim DH6, Min BH7, Lee JH7, Rhee PL7, Kim JJ7, Choi DI8, Tan IB9, Das K10, Tan P11, Jung SH2, Kang WK1, Kim S5.
    View PubMed
  • Cancer Chemother Pharmacol. 2014 Jan;73(1):163-9. doi: 10.1007/s00280-013-2334-3. Epub 2013 Nov 8. A randomized phase II study of weekly docetaxel/cisplatin versus weekly docetaxel/oxaliplatin as first-line therapy for patients with advanced gastric cancer Kim YS11, Sym SJ, Park SH, Park I, Hong J, Ahn HK, Park J, Cho EK, Lee WK, Chung M, Lee JH, Shin DB.
    View PubMed
  • Cancer Res Treat. 2014 Jan;46(1):27-32. doi: 10.4143/crt.2014.46.1.27. Epub 2014 Jan 15. Chemotherapy in Advanced Gastric Cancer Patients Associated with Disseminated Intravascular Coagulation Hwang IG11, Choi JH2, Park SH3, Oh SY4, Kwon HC4, Lee SI5, Lim do H5, Lee GW6, Kang JH6.
    View PubMed
  • Cancer Chemother Pharmacol. 2014 Jan;73(1):163-9. doi: 10.1007/s00280-013-2334-3. Epub 2013 Nov 8. A randomized phase II study of weekly docetaxel/cisplatin versus weekly docetaxel/oxaliplatin as first-line therapy for patients with advanced gastric cancer Kim YS11, Sym SJ, Park SH, Park I, Hong J, Ahn HK, Park J, Cho EK, Lee WK, Chung M, Lee JH, Shin DB.
    View PubMed
  • Lancet Oncol. 2014 Jan;15(1):8-10. doi: 10.1016/S1470-2045(13)70580-1. Epub 2013 Dec 10. Second-line chemotherapy for patients with oesophagogastric adenocarcinoma 1,Park SH1.
    View PubMed
  • Cancer Chemother Pharmacol. 2014 Jan;73(1):125-30. doi: 10.1007/s00280-013-2328-1. Epub 2013 Oct 27. Randomized double-blinded, placebo-controlled phase II trial of simvastatin and gemcitabine in advanced pancreatic cancer patients Hong JY11, Nam EM, Lee J, Park JO, Lee SC, Song SY, Choi SH, Heo JS, Park SH, Lim HY, Kang WK, Park YS.
    View PubMed
  • Oncologist. 2013;18(11):1229-34. doi: 10.1634/theoncologist.2013-0224. Epub 2013 Oct 9. Treatment of Dexamethasone-Induced Hiccup in Chemotherapy Patients by Methylprednisolone Rotation Lee GW11, Oh SY, Kang MH, Kang JH, Park SH, Hwang IG, Yi SY, Choi YJ, Ji JH, Lee HY, Bruera E.
    View PubMed
  • Cancer Chemother Pharmacol. 2013 Feb;71(2):481-8. doi: 10.1007/s00280-012-2027-3. Epub 2012 Nov 29. A randomized phase II study of biweekly irinotecan monotherapy or a combination of irinotecan plus 5-fluorouracil/leucovorin (mFOLFIRI) in patients with metastatic gastric adenocarcinoma refractory to or progressive after first-line chemotherapy Sym SJ11, Hong J, Park J, Cho EK, Lee JH, Park YH, Lee WK, Chung M, Kim HS, Park SH, Shin DB.
    View PubMed
  • Invest New Drugs. 2012 Dec;30(6):2377-83. doi: 10.1007/s10637-012-9795-9. Epub 2012 Jan 25. Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study group Park SH11, Ryu MH, Ryoo BY, Im SA, Kwon HC, Lee SS, Park SR, Kang BY, Kang YK.
    View PubMed
  • Cancer Res Treat. 2012 Dec;44(4):235-41. doi: 10.4143/crt.2012.44.4.235. Epub 2012 Dec 31. Outcomes of Third-Line Docetaxel-Based Chemotherapy in Advanced Gastric Cancer Who Failed Previous Oxaliplatin-Based and Irinotecan-Based Chemotherapies Lee MJ11, Hwang IG, Jang JS, Choi JH, Park BB, Chang MH, Kim ST, Park SH, Kang MH, Kang JH.
    View PubMed
  • Cancer Chemother Pharmacol. 2012 Oct;70(4):583-90. Epub 2012 Aug 12. A phase II trial of ixabepilone in Asian patients with advanced gastric cancer previously treated with fluoropyrimidine-based chemotherapy Kim YH11, Muro K, Yasui H, Chen JS, Ryu MH, Park SH, Chu KM, Choo SP, Sanchez T, DelaCruz C, Mukhopadhyay P, Lainas I, Li CP.
    View PubMed
  • Invest New Drugs. 2012 Oct;30(5):1984-90. doi: 10.1007/s10637-011-9757-7. Epub 2011 Oct 20. Phase II study of a cremophor-free, polymeric micelle formulation of paclitaxel for patients with advanced urothelial cancer previously treated with gemcitabine and platinum Lee JL11, Ahn JH, Park SH, Lim HY, Kwon JH, Ahn S, Song C, Hong JH, Kim CS, Ahn H.
    View PubMed
  • Ann Oncol. 2012 Aug;23(8):2108-14. doi: 10.1093/annonc/mdr586. Epub 2012 Jan 6. Multicenter phase II study of sunitinib in patients with non-clear cell renal cell carcinoma Lee JL11, Ahn JH, Lim HY, Park SH, Lee SH, Kim TM, Lee DH, Cho YM, Song C, Hong JH, Kim CS, Ahn H.
    View PubMed
  • Cancer. 2012 Jun 1;118(11):2828-36. doi: 10.1002/cncr.26614. Epub 2011 Oct 21. Polymorphic markers associated with severe oxaliplatin-induced, chronic peripheral neuropathy in colon cancer patients Won HH11, Lee J, Park JO, Park YS, Lim HY, Kang WK, Kim JW, Lee SY, Park SH.
    View PubMed
  • J Clin Oncol. 2012 May 1;30(13):1513-8. doi: 10.1200/JCO.2011.39.4585. Epub 2012 Mar 12. Salvage Chemotherapy for Pretreated Gastric Cancer: A Randomized Phase III Trial Comparing Chemotherapy Plus Best Supportive Care With Best Supportive Care Alone Kang JH11, Lee SI, Lim do H, Park KW, Oh SY, Kwon HC, Hwang IG, Lee SC, Nam E, Shin DB, Lee J, Park JO, Park YS, Lim HY, Kang WK, Park SH.
    View PubMed
  • Acta Oncol. 2012 Apr;51(4):528-36. doi: 10.3109/0284186X.2011.636753. Epub 2011 Dec 7. Imatinib efficacy by tumor genotype in Korean patients with advanced gastrointestinal stromal tumors (GIST): The Korean GIST Study Group (KGSG) study Kang HJ11, Ryu MH, Kim KM, Park YS, Choi J, Ryoo BY, Kim WH, Im SA, Bang YJ, Park SH, Lee JH, Chung IJ, Bae HI, Kim JG, Lee KH, Song HS, Kwon HC, Baek JH, Shin DB, Lee KE, Kang YK.
    View PubMed
  • Cancer Chemother Pharmacol. 2012 Jan;69(1):91-7. doi: 10.1007/s00280-011-1668-y. Epub 2011 May 24. Combining capecitabine, oxaliplatin, and gemcitabine (XELOXGEM) for colorectal carcinoma patients pretreated with irinotecan: a multicenter phase I/II trial Kim SH11, Shin SJ, Kim SY, Lee SH, Park YS, Park SH, Lee KH, Kim TW, Hong YS, Ahn JB.
    View PubMed
  • J Obstet Gynaecol Res. 2011 Dec;37(12):1833-7. doi: 10.1111/j.1447-0756.2011.01615.x. Epub 2011 Jul 27. Metastatic urachal carcinoma of the ovary Jo EJ11, Choi CH, Bae DS, Park SH, Hong SR, Lee JH.
    View PubMed
  • Cancer Res Treat. 2011 Jun;43(2):96-101. doi: 10.4143/crt.2011.43.2.96. Epub 2011 Jun 30. A Retrospective Study of First-Line Combination Chemotherapy in Advanced Colorectal Cancer: A Korean Single-Center Experience Lee S 2nd11, Park SH, Lim do H, Park KW, Lee J, Park JO, Park YS, Lim HY, Kang WK.
    View PubMed
  • Med Oncol. 2011 Mar;28(1):342-50. doi: 10.1007/s12032-010-9453-z. Epub 2010 Mar 3. Irinotecan plus carboplatin in patients with extensive-disease small-cell lung cancer Kim YS11, Park SH, Kyung SY, Sym SJ, Lee SP, Park JW, Jung SH, Park J, Cho EK, Lee JH, Shin DB.
    View PubMed
  • Cancer Res Treat. 2010 Dec;42(4):185-90. doi: 10.4143/crt.2010.42.4.185. Epub 2010 Dec 31. Oxaliplatin-Induced Chronic Peripheral Neurotoxicity: A Prospective Analysis in Patients with Colorectal Cancer Baek KK11, Lee J, Park SH, Park JO, Park YS, Lim HY, Kang WK, Cho YB, Yun SH, Kim HC, Lee WY, Chun HK.
    View PubMed
  • Eur J Clin Pharmacol. 2010 Dec;66(12):1235-45. doi: 10.1007/s00228-010-0885-3. Epub 2010 Sep 9. Population pharmacokinetics of CPT-11 (irinotecan) in gastric cancer patients with peritoneal seeding after its intraperitoneal administration Ahn BJ11, Choi MK, Park YS, Lee J, Park SH, Park JO, Lim HY, Kang WK, Ko JW, Yim DS.
    View PubMed
  • Jpn J Clin Oncol. 2010 Nov;40(11):1031-6. doi: 10.1093/jjco/hyq083. Epub 2010 Jun 9. The Efficacy of the Frontline Platinum-based Combination Chemotherapy in Malignant Peritoneal Mesothelioma Kim ST11, Park JY, Lee J, Park JO, Park YS, Lim HY, Kang WK, Park SH.
    View PubMed
  • BMC Cancer. 2010 Oct 26;10:583. doi: 10.1186/1471-2407-10-583. Retrospective analyses of cisplatin-based doublet combination chemotherapy in patients with advanced gastric cancer Lim do H11, Park SH, Park KW, Kang JH, Oh SY, Hwang IG, Kwon JM, Lee SC, Lee HY, Kim HS, Lim HY, Kang WK.
    View PubMed
  • Cancer Res Treat. 2010 Jun;42(2):101-6. doi: 10.4143/crt.2010.42.2.101. Epub 2010 Jun 30. Predictive Value of the ERCC1 Expression for Treatment Response and Survival in Advanced Gastric Cancer Patients Receiving Cisplatin-based First-line Chemotherapy Yun J11, Kim KM, Kim ST, Kim JH, Kim JA, Kong JH, Lee SH, Won YW, Sun JM, Lee J, Park SH, Park JO, Park YS, Lim HY, Kang WK.
    View PubMed
  • Asia Pac J Clin Oncol. 2010 Mar;6(1):19-27. doi: 10.1111/j.1743-7563.2010.01276.x. Clinical characteristics and prognostic factors for primary appendiceal carcinoma Ko YH11, Park SH, Jung CK, Won HS, Hong SH, Park JC, Roh SY, Woo IS, Kang JH, Hong YS, Byun JH.
    View PubMed
  • Cancer Res Treat. 2010 Mar;42(1):24-9. doi: 10.4143/crt.2010.42.1.24. Epub 2010 Mar 31. Oxaliplatin, 5-fluorouracil and Leucovorin (FOLFOX-4) Combination Chemotherapy as a Salvage Treatment in Advanced Gastric Cancer Kim YS11, Hong J, Sym SJ, Park SH, Park J, Cho EK, Lee JH, Shin DB.
    View PubMed
  • Eur J Cancer. 2010 Mar;46(5):885-91. doi: 10.1016/j.ejca.2009.12.015. Epub 2010 Jan 7. A randomised phase II study of combination chemotherapy with epirubicin, cisplatin and capecitabine (ECX) or cisplatin and capecitabine (CX) in advanced gastric cancer Yun J11, Lee J, Park SH, Park JO, Park YS, Lim HY, Kang WK
    View PubMed
  • J Korean Med Sci. 2009 Jun;24(3):448-52. doi: 10.3346/jkms.2009.24.3.448. Epub 2009 Jun 12. Epidermal Growth Factor Receptor Mutations and the Clinical Outcome in Male Smokers with Squamous Cell Carcinoma of Lung Park SH11, Ha SY, Lee JI, Lee H, Sim H, Kim YS, Hong J, Park J, Cho EK, Shin DB, Lee JH.
    View PubMed
  • BMC Cancer. 2009 Apr 9;9:110. doi: 10.1186/1471-2407-9-110. A retrospective analysis of second-line chemotherapy in patients with advanced gastric cancer Ji SH11, Lim do H, Yi SY, Kim HS, Jun HJ, Kim KH, Chang MH, Park MJ, Uhm JE, Lee J, Park SH, Park JO, Park YS, Lim HY, Kang WK.
    View PubMed
  • Cancer Chemother Pharmacol. 2008 Nov;62(6):1009-14. doi: 10.1007/s00280-008-0690-1. Epub 2008 Feb 8. Salvage treatment with topotecan in patients with irinotecan-refractory small cell lung cancer Park SH11, Cho EK, Kim Y, Kyung SY, An CH, Lee SP, Park JW, Jeong SH, Lee JI, Choi SJ, Park J, Shin DB, Lee JH.
    View PubMed
  • Lung Cancer. 2008 Oct;62(1):72-7. doi: 10.1016/j.lungcan.2008.02.001. Epub 2008 Mar 14. Phase II trial of weekly docetaxel and gemcitabine for previously untreated, advanced non-small cell lung cancer Park SH11, Hong J, Kim YS, Kim Y, Kyung SY, An CH, Lee SP, Park JW, Jeong SH, Park J, Cho EK, Shin DB, Lee JH.
    View PubMed
  • In reply to Mauer et al. "Statistical methodology is crucial in prognostic factor-analysis of health-related quality of life"
  • Am J Clin Oncol. 2004 Oct;27(5):477-80. Docetaxel plus cisplatin as second-line therapy in metastatic or recurrent advanced gastric cancer progressing on 5-fluorouracil-based regimen Park SH11, Kang WK, Lee HR, Park J, Lee KE, Lee SH, Park JO, Kim K, Kim WS, Chung CW, Im YH, Lee MH, Park CH, Park K.
    View PubMed
  • J Korean Med Sci. 2004 Feb;19(1):79-82. The outcomes of hypertransfusion in major ABO incompatible allogeneic stem cell transplantation Park SH11, Lee MH, Lee SH, Lee KE, Park J, Park JO, Kim K, Kim WS, Jung CW, Im YH, Kang WK, Park K, Kim SW, Lee KH, Lee JH.
    View PubMed
  • Bone Marrow Transplant. 2003 Nov;32(9):889-95. Autologous peripheral blood stem cell transplantation with induction of autologous graft-versus-host disease in acute myeloid leukemia Park J11, Lee MH, Lee HR, Park SH, Lee SH, Lee KE, Lee H, Park JO, Kim K, Jung CW, Im YH, Kang WK, Ko YH, Park K.
    View PubMed
  • Ann Oncol. 2003 Sep;14(9):1373-7. Postoperative chemoradiotherapy for gastric cancer Park SH11, Kim DY, Heo JS, Lim DH, Park CK, Lee KW, Choi SH, Sohn TS, Kim S, Noh JH, Kim YI, Park JO, Kim K, Kim WS, Jung CW, Im YH, Lee MH, Park K, Park CH, Kang WK.
    View PubMed
  • Bone Marrow Transplant. 2002 Jan;29(2):137-43. A randomized trial of heparin plus ursodiol vs heparin alone to prevent hepatic veno-occlusive disease after hematopoietic stem cell transplantation Park SH11, Lee MH, Lee H, Kim HS, Kim K, Kim WS, Jung CW, Im YH, Yoon SS, Kang WK, Park K, Park CH, Kim SW.
    View PubMed